Electronic Signature Page

Full Title
Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of idalopirdine in patients with mild-moderate Alzheheimer's disease treated with donepezil; Study 2

Short Title
14862A - Statistical Analysis Plan

Study Number 14862A

The following persons have electronically signed this document

Server Date and Time	Signed by
29-Apr-2016 10:12:36	LLRA Lars Lau Raket
Reason for Signature	Biostatistic Approval

29-Apr-2016 12:54:42	MBRS Maiken Brix Schou
Reason for Signature	Clinical Approval

29-Apr-2016 15:34:55	AKTH Anna Karina Trap Huusom
Reason for Signature	Management Approval

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Statistical Analysis Plan

Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of idalopirdine in patients with mild-moderate Alzheimer's disease treated with donepezil; Study 2

Idalopirdine

Study No.:	14862A
Sponsor:	H. Lundbeck A/S (Lundbeck) 2500 Valby (Copenhagen), Denmark
Biostatistician:	Lars Lau Raket, Biostatistics
SAP date:	29 April 2016

Table of Contents

List of Panels **6**

List of Abbreviations and Definitions of Terms **7**

1 Objectives **9**
1.1 Primary Objective 9
1.2 Secondary Objective 9
1.3 Other Objective 9
1.4 Safety Objective 9

2 Study Design **9**

3 Endpoints **11**
3.1 Primary Endpoint 11
3.2 Key Secondary Endpoints 11
3.3 Secondary Endpoint(s) 11
3.4 Safety Endpoints 12

4 Analysis Sets **12**

5 Descriptive Statistics **13**

6 Patient Disposition **13**
6.1 Summary of Patient Disposition 13
6.2 Withdrawal 13

7 Demographics and Other Baseline Characteristics **14**

8 Recent and Concomitant Medication **14**

9 Exposure and Compliance **15**

10 Efficacy **16**
10.1 General Efficacy Analysis Methodology 16
10.2 Analysis Methodology for the Primary Endpoint 17
10.2.1 Analysis of the Primary Endpoint 17
10.2.2 Rationale for Selected Analysis Method for the Primary Endpoint 18
10.2.3 Subgroup Analyses and Model Assumptions for Analysis of the Primary Endpoint 18
10.2.4 Sensitivity Analyses of the Primary Endpoint 19
10.3 Analysis Methodology for the Key Secondary Endpoints 20
10.3.1 Analysis of the Key Secondary Endpoints 20
10.3.2 Rationale for Selected Analysis Method for the Key Secondary Endpoints 21
10.3.3 Subgroup Analyses and Model Assumptions for Analysis of the Key Secondary Endpoints 21
10.3.4 Sensitivity Analyses of the Key Secondary Endpoints 21
10.4 Testing Strategy 21
10.5 Analysis of the Secondary Endpoints 22

11 Safety **23**
11.1 Adverse Events 23
11.1.1 General Methodology for Adverse Events 23

11.1.2 Coding of Adverse Events....24
11.1.3 Classification of Adverse Events....24
11.1.4 All Adverse Events....24
11.1.5 Pre-treatment Adverse Events....24
11.1.6 Treatment-emergent Adverse Events....24
11.1.7 Deaths....25
11.1.8 Serious Adverse Events....25
11.1.9 Adverse Events Leading to Withdrawal....25
11.1.10 Adverse Events of Special Interest....25
11.2 General Methodology for Other Safety Data....25
11.3 Clinical Safety Laboratory Test Data....26
11.3.1 Data Presentation....26
11.3.2 Urinalysis....27
11.3.3 Evaluation of Potential Drug-induced Liver Injury (DILI)....27
11.4 Vital Signs and Weight....29
11.5 ECGs....29
11.6 Neurological Examinations....30
11.7 Other Safety Endpoint....30
11.7.1 Columbia-Suicide Severity Rating Scale (C-SSRS)....30

12 Pharmacokinetic and Pharmacodynamic Analyses....31

13 Pharmacoeconomic Analyses....31

14 Interim Analyses....32

15 Sample Size Considerations....32

16 Data and Analysis Standards and Statistical Software....33

17 Changes to Analyses Specified in the Protocol....33

18 Details on Data Handling....34
18.1 Definition of Baseline....34
18.2 Derived Variables....34
18.2.1 Mini-Mental State Examination (MMSE) Total Score and MMSE Stratum....34
18.2.2 Alzheimer's Disease Assessment Scale – Cognitive Sub-scale (ADAS-Cog) Total Score....35
18.2.3 Alzheimer's Disease Co-operative Society – Activities of Daily Living ($ADCS\text{-}ADL_{23}$) Total Score....37
18.2.3.1 Activities of Daily Living – Basic (ADL-B) Total Score....41
18.2.3.2 Activities of Daily Living – Instrumental (ADL-I) Total Score....41
18.2.4 Composite Score for ADAS-Cog and $ADCS\text{-}ADL_{23}$....41
18.2.5 Neuropsychiatric Inventory (NPI) Total Score....41
18.2.6 NPI Caregiver Distress Total Score....42
18.2.7 EQ-5D Utility Score....42
18.2.8 Dependence Level Score....43
18.3 Assigning Data to Visits....45
18.3.1 Rating Scales....45
18.3.2 Safety Variables....46
18.4 Handling of Missing or Incomplete Dates/Times....47
18.4.1 IMP Start and Stop Dates....47
18.4.2 Donepezil Start Date....47
18.4.3 Date of Alzheimer Diagnosis....47

18.4.4 Withdrawal Date 47
18.4.5 Medication Start and Stop Dates 47
18.4.6 Adverse Event Start and Stop Dates 48
18.5 Compliance 48
18.6 Grouping of Small Sites 49

References 50

Appendices

Appendix I **Statistical Analysis Plan Authentication and Authorisation** **51**
Appendix II **Study Flow Chart** **53**
Appendix III **SAS® Code** **58**
Appendix IV **PCS Criteria** **63**

List of Panels

Panel 1 Study Design....10
Panel 2 Secondary Endpoints....16
Panel 3 Sequentially Rejective Multiple Test Procedure....22
Panel 4 Graphical Presentations for the Clinical Safety Laboratory Tests....27
Panel 5 Graphical Presentations for Vital Signs and Weight....29
Panel 6 Graphical Presentations for ECG Parameters....30
Panel 7 C-SSRS Items....31
Panel 8 Definition of ADAS-Cog Item Scores....36
Panel 9 Definition of ADCS-ADL_{23} Item Scores....38
Panel 10 Items Dependence Scale....44
Panel 11 Visit Windows for assessments collected at Visit 3, Visit 5, and Visit 7....46
Panel 12 Visit Windows for assessments collected only at Visit 5, and Visit 7....46
Panel 13 Visit Windows for Clinical Safety Data....46
Panel 14 Handling of Missing Dates in Classification of Medications....48

List of Abbreviations and Definitions of Terms

aCRF	Annotated case report form
ADAS-Cog	Alzheimer's Disease Assessment Scale, Cognitive subscale
ADCS-ADL_{23}	Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory
ADCS-CGIC	Alzheimer's Disease Cooperative Study – Clinical Global Impression of Change
ADL-B	Basic ADCS-ADL_{23} (questions 1 – 6)
ADL-I	Instrumental ADCS-ADL_{23} (questions 7 – 23)
ALT	alanine aminotransferase
ANCOVA	analysis of covariance
ALP	alkaline phosphatase
APRS	all-patients-randomised set
APTS	all-patients-treated set
AST	aspartate aminotransferase
ATC	anatomical therapeutic chemical
AUC	area under the curve
BILI	Total serum bilirubin
BMI	body mass index
BP	blood pressure
bpm	beats per minute
BUN	blood urea nitrogen
CI	confidence interval
CRP	C-reactive protein
C-SSRS	Columbia-Suicide Severity Rating Scale
CYP	cytochrome P450 isoenzyme
DMC	Data Monitoring Committee
ECG	electrocardiogram
eCRF	electronic case report form
EQ-5D-3L	EuroQol questionnaire
FAS	full-analysis set
FDA	United States Food and Drug Administration
GGT	Gamma glutamyl transferase
HR	heart rate
IMP	investigational medicinal product
INR	international normalised ratio of prothrombin time
MAR	missing at random
MCMC	Markov chain Monte Carlo
MedDRA	Medical Dictionary for Regulatory Activities
MI	multiple imputation
MMRM	mixed model for repeated measurements

MMSE	Mini Mental State Examination
mRNA	messenger ribonucleic acid
NPI	Neuropsychiatric Inventory
PBO	placebo
PCS	potentially clinically significant
PMM	pattern mixture model
PYE	patient years of exposure
QRS	specific ECG interval describing ventricular depolarisation
QT	specific ECG interval describing ventricular depolarisation/repolarisation
QT_{cB}	heart-rate corrected QT interval using Bazett's correction formula
QT_{cF}	heart-rate corrected QT interval using Fridericia's correction formula
REML	restricted maximum likelihood
RUD Lite	Resource Utilisation in Dementia Lite
SAE	serious adverse event
SAP	Statistical Analysis Plan
SAS	statistical software package from the SAS® Institute
SD	standard deviation
SE	standard error
SOC	system organ class
TEAE	treatment-emergent adverse event
ULN	Upper limit of normal
VAS	visual analogue scale
WHO	World Health Organization
WHO-DD	World Health Organization Drug Dictionary

1 Objectives

1.1 Primary Objective

To establish the efficacy of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-moderate Alzheimer's disease.

1.2 Secondary Objective

To investigate the effect of idalopirdine as adjunctive therapy to donepezil on neuropsychiatric symptoms in patients with mild-moderate Alzheimer's disease

1.3 Other Objective

To explore population pharmacokinetics (PK)/ pharmacodynamics (PD)

1.4 Safety Objective

To evaluate the safety and tolerability of idalopirdine as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's disease

2 Study Design

This is an interventional, prospective, multi-national, multi-site, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of idalopirdine as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's disease.

The total study duration per patient from baseline to the end of follow-up will be approximately 28 weeks. The patients will be treated with the double blind IMP as add on therapy to the base treatment donepezil 10 mg. The study will include the following periods:

- 2-week screening period
- 24-week double-blind (idalopirdine 10 or 30 mg/day or placebo) treatment period as add-on to donepezil 10 mg/day
- 4-week safety follow-up period (only relevant for patients who do not continue in the 14861B extension study)

The study design is presented in Panel 1 and the scheduled assessments are summarised in Appendix II (study flow chart).

Panel 1 Study Design



The patients were randomised symmetrically via a centralised randomisation system (Interactive Voice Response System [IVRS]) at Visit 2 (Day 0) to one of three treatment groups: Lu AE58054 30 mg/day, Lu AE58054 10 mg/day or placebo. Randomisation was stratified by site and Mini Mental State Exam (MMSE) stratum (<19, ≥19). The randomisation was restricted such that at most 50% of the patients are in the MMSE 19-22 (mild) stratum.

The group of patients who withdrew during the *treatment period* will be described as *withdrawn from treatment*. The complementary group will be described as *completed treatment*.

The study includes a follow-up of withdrawn patients, except for those who withdraw their consent, 4 weeks after the Withdrawal Visit (Withdrawal Follow-up Visit), and at the projected time of the primary endpoint (Drop-out Retrieval Visit). The drop-out retrieval visit data collection only applies if a patient withdraws prior to Visit 6 (week 18). The Withdrawal Follow-Up Visit and Drop-out Retrieval Visit includes collection of data to address the primary and key secondary endpoints.

The efficacy data collected after withdrawal from treatment will be designated *follow-up efficacy data* (that is, data collected at the Withdrawal Follow-up Visit and at the Drop-out Retrieval Visit). The *follow-up efficacy data* will only be used for sensitivity analysis.

3 Endpoints

3.1 Primary Endpoint

The primary endpoint addresses the primary objective of the study.

- Cognition:
  - Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) total score

3.2 Key Secondary Endpoints

The key secondary endpoints address the primary objective of the study.

- Global impression:
  - Alzheimer's Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC) score at Week 24
- Function
  - Change from baseline to Week 24 in Alzheimer's Disease Cooperative Study – Activities of Daily Living Inventory (ADCS-ADL_{23}) total score

3.3 Secondary Endpoint(s)

The secondary endpoints address the secondary objective, are supportive of the primary objective or address other objectives of the study.

- Endpoints addressing the secondary objective:
  - Change from baseline to Week 24 in Neuropsychiatric Inventory (NPI) total score
  - Change from baseline in single NPI items at Week 24
  - Change from baseline to Week 24 in NPI single items in patients with an item score of at least 2 at baseline
  - Emergence of individual NPI items (score ≥ 3) at Week 24. The analyses will be based on patients with an item score of < 3 at baseline.
  - Change from baseline in NPI caregiver distress total score at Week 24.
- Endpoints that are supportive of the primary objective:
  - Clinical response at Week 24 (ADAS-Cog change $\leq$-4 and ADCS-ADL_{23} change $\geq$0 and ADCS-CGIC $\leq$4)
  - Clinical response at Week 24 where response is defined using cut-offs of $\leq$ -3, $\leq$ -2 , $\leq$ -1 for ADAS-Cog change and ADCS-ADL_{23} change $\geq$0 and ADCS-CGIC$\leq$4)
  - Clinical worsening at Week 24 (ADAS-Cog change $\geq$4 and ADCS-ADL_{23} change $<$0 and ADCS-CGIC $>$4)
  - Change from baseline to Week 24 in Mini Mental State Examination (MMSE) total score
  - Change from baseline to Week 24 in EQ-5D-3L utility score
  - Change from baseline to Week 24 in EQ-5D-3L VAS

- Area under the curve (AUC) from baseline to week 24 for the changes from baseline in ADAS-Cog total score
- AUC from baseline to Week 24 for the changes from baseline in ADCS-ADL_{23} total score
- AUC from baseline to Week 24 for the ADCS-CGIC minus four (as ADCS-CGIC is an assessment of changes, i.e. no change in health state corresponds to a score of 0)
- AUC from baseline to Week 24 in composite score for ADAS-Cog and ADCS-ADL_{23}
- Change from baseline to Week 24 in composite score for ADAS-Cog and ADCS-ADL_{23}
- Change from baseline to Week 24 in Basic ADCS-ADL_{23} (ADL-B)
- Change from baseline to Week 24 in Instrumental ADCS-ADL_{23} (I- ADL)

– Endpoints addressing other objectives:
- Plasma concentrations of idalopirdine and donepezil

3.4 Safety Endpoints

Endpoints addressing the safety objectives:
- Adverse events (AEs)
- Absolute values and changes from baseline clinical safety laboratory tests, vital signs, weight, and electrocardiogram (ECG) parameters
- Potentially clinically significant clinical safety laboratory test values, vital signs, weight, and ECG parameter values
- Columbia Suicide Severity Rating Scale (C-SSRS)

4 Analysis Sets

The classification will be based on IMP intake and post-baseline assessments of the primary efficacy variable (ADAS-Cog) in the Treatment Period.

The sets of patients to be analysed are defined as follows:
- *all-patients-randomised set* (APRS) – all randomised patients
- *all-patients-treated set* (APTS) – all patients in the APRS who took at least one dose of IMP
- *full-analysis set* (FAS) – all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of ADAS-Cog

The patients and data will be classified into the analysis sets according to the definitions above after the study database has been released but before the blind has been broken.

If a patient received the incorrect IMP (IMP not randomised to), all analyses will be based on the randomised treatment but information about the actual treatment and the start-and-stop date(s) when incorrect IMP was received will be included as a footnote in output where relevant. Additional listing will also be prepared if needed.

5 Descriptive Statistics

Unless otherwise specified, summary statistics (n, and at a minimum: arithmetic mean, standard deviation [SD], median, minimum and maximum) will be presented for continuous variables, and counts and percentages will be presented for categorical variables.

Unless otherwise specified, data listings will include site, treatment group, patient screening number, MMSE stratum, sex, age, and race.

6 Patient Disposition

6.1 Summary of Patient Disposition

Patient disposition will be summarised by treatment group and include the number of patients in each analysis set defined in Section 4, and the number of patients in the APTS who completed or withdrew from treatment.

Patient disposition will also be summarised by MMSE stratum.

6.2 Withdrawal

The number of patients who withdrew from treatment will be summarised by treatment group and primary reason for withdrawal as well as by treatment group and all reasons for withdrawal. Reasons for withdrawal collected in the study were adverse events, protocol violation, withdrawal of consent, lost to follow-up, and other reasons.

Patients who withdrew from treatment will be listed and the listing will include the number of days in the study until withdrawal from treatment, exposure to IMP (see definition in Chapter 9), the primary reason for withdrawal, and all reasons for withdrawal.

The cumulative number of withdrawals from treatment at visit weeks 4, 8, 12, 18, and 24 for each primary reason of withdrawal will be presented by treatment group. The Withdrawal Visit will be assigned to the closest scheduled visit not attended in the Treatment Period.

Kaplan-Meier plots of time to withdrawal from treatment will be presented by treatment group. The time will be calculated from the date of first dose of IMP to the date of completion or withdrawal from treatment. Patients who completed treatment will be regarded as censored.

Nelson-Aalen cause-specific cumulative hazard plots of time to withdrawal from treatment will be generated for each primary reason. The time will be calculated from the date of first dose of IMP to the date of completion or withdrawal from treatment.

All tables, graphs, and listings will be based on the APTS.

All analyses will be repeated by MMSE stratum.

7 Demographics and Other Baseline Characteristics

Demographics (age, age groups [<65, 65-74, 75-84, and ≥85], sex, ethnicity, and race), patient characteristics (weight, height, BMI, smoking, other nicotine use, alcohol use, years of education and marital status), Alzheimer's disease and family history of Alzheimer's disease (MMSE stratum, MMSE total score at baseline, years since diagnosis [see paragraph 18.4.3], previous treatment with memantine, previous treatment with Acetycholinesterase inhibitors (AChEIs) other than donepezil, participation in randomized Alzheimer's disease trials, duration of donepezil treatment [see paragraph 18.4.2], and number of first degree relatives with a diagnosis in Alzheimer's disease), and efficacy variables at baseline wiill be summarised in total and by treatment group.

The medical, neurological, and psychiatric histories as well as the concurrent medical, neurological, and psychiatric disorders will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), Version 17.1 or later, and summarised by treatment group.

A medical, neurological, or psychiatric history is a disorder that ended prior to the Screening Visit. A concurrent medical, neurological, or psychiatric disorder is a disorder that is on-going at the Screening Visit.

Demographics and other baseline characteristics will be summarised based on the APTS.

All summaries will be repeated by MMSE stratum.

8 Recent and Concomitant Medication

Recent and concomitant medication will be coded using the WHO Drug Dictionary (WHO-DDE), Version 12.1, or later.

Medications will be classified according to the start and stop time and summarised by anatomical therapeutic chemical (ATC) code, generic drug name, and treatment group:

- medication discontinued prior to first dose of IMP
- concomitant medication continued after first dose of IMP
- concomitant medication started at or after first dose of IMP and at or before the completion/withdrawal visit
- Treatment for Alzheimer's disease (identified by ATC code N06D) started after the Withdrawal Visit in withdrawn patients

For details about handling of missing dates, see sections 18.4.1 (IMP start date), and 18.4.3 (medication start and stop dates).

Tables will be based on the APTS.

9 Exposure and Compliance

Exposure to IMP will be defined as:

date of last dose of IMP – date of first dose of IMP + 1

For handling of missing IMP start or stop date, see paragraph 18.4.1.

Exposure to IMP will be summarised by treatment group using descriptive statistics, and include the patient years of exposure (PYE) to IMP. PYE will be calculated as the sum of the number of days of exposure to IMP for each patient, divided by 365.25 days.

In addition, exposure to IMP will be categorised in intervals (1 to 27, 28 to 55, 56 to 83, 84 to 125, 126 to 167 and ≥168 days) and summarised by treatment group.

Exposure to donepezil will be defined and summarised in the corresponding way as exposure to IMP.

Non-compliance days are days on which no IMP has been taken.

Compliance with IMP (%) in the *treatment period* will be defined as the compliance for the interval between the Date of Randomisation + 1 (the first IMP should be taken the day after the randomisation) and the Completion/Withdrawal Visit:

{date of Completion/Withdrawal Visit – date of Randomisation – total number of days of non-compliance} / {date of Completion/Withdrawal Visit – date of Randomisation} × 100%

Compliance with IMP (%) will also be defined for intervals between consecutive scheduled visits in the *treatment period*. The first visit interval will be the interval between date of randomisation + 1 and Date of Visit 3, and thereafter intervals between $Visit_i$ and $Visit_{i+1}$, i=3, 4, 5, and 6.

For details on data handling issues, see sections 18.4.4 and 18.5.

Compliance with IMP will be summarized by treatment group, both by visit interval and for the entire *treatment period*.

Compliance with donepezil will be defined and summarised in the corresponding way as compliance with IMP.

Exposure and compliance will be summarised based on the APTS.

10 Efficacy

10.1 General Efficacy Analysis Methodology

Primary, key-secondary, and secondary endpoints and the corresponding type (continuous, categorical, or binary) are summarised in Panel 2.

Panel 2 Secondary Endpoints

Endpoint	Type
Primary	
Change from baseline to Week 24 in ADAS-Cog total score	1
Key-secondary	
ADCS-CGIC score at Week 24 (assessment of patient change compared to patient's condition at the baseline visit)	1, 2
Change from Baseline to Week 24 in ADCS-ADL_{23} total score	1
Secondary	
Change from baseline to Week 24 in NPI total score	1
Change from baseline in single NPI items at Week 24 (12 endpoints)	1
Change from baseline to Week 24 in NPI single items in patients with an item score of at least 2 at baseline (12 endpoints)	1
Emergence of individual NPI items (score≥3). The analyses will be based on patients with an item score of <3 at baseline (12 endpoints)	3
Change from baseline in NPI caregiver distress total score	1
Clinical response at Week 24 (ADAS-Cog change ≤ -4 and ADCS-ADL_{23} change ≥0 and ADCS-CGIC≤4)	3
Clinical response at Week 24 where response is defined using cut-offs of ≤-3, ≤-2, ≤-1 for ADAS-Cog change, ADCS-ADL_{23} change ≥0 and ADCS-CGIC≤4 (three endpoints)	3
Clinical worsening at Week 24 (ADAS-Cog change ≥4 and ADCS-ADL_{23} change <0 and ADCS-CGIC>4)	3
Change from baseline to Week 24 in MMSE total score	1
Change from baseline to Week 24 in EQ-5D utility score	1
Change from baseline to Week 24 in EQ-5D VAS	1
Area under the curve (AUC) from baseline to week 24 for the changes from baseline in ADAS-Cog total score	1
AUC from baseline to week 24 for the changes from baseline in ADCS-ADL_{23} total score	1
AUC from baseline to week 24 for the ADCS-CGIC scores minus four (as ADCS-CGIC is an assessment of changes, i.e. no change in health state corresponds to a score of 0)	1
Composite score at Week 24 for ADAS-Cog and ADCS-ADL_{23}	1
Change from baseline to Week 24 in Basic ADCS-ADL_{23} (ADL-B)	1
Change from baseline to Week 24 in Instrumental ADCS-ADL_{23} (ADL-I)	1
Plasma concentrations of idalopirdine and donepezil	1

1 = continuous; 2 = categorical; 3 = binary

For details about data handling issues in the derivation of variables and assigning data o visits (weeks), see section 18.2 and 18.3.1.

Unless otherwise specified, all the efficacy analyses will be based on the FAS.

All the tables and graphs will be presented by treatment group.

The *follow-up efficacy data* will only be used for sensitivity analyses (see last section in Chapter 2).

The absolute values and change from baseline values (if defined) for efficacy variables (MMSE total score, ADAS-Cog total score, ADCS-ADL_{23} total score, ADL-I total score, ADL-B total score, ADCS-CGIC, NPI total score, NPI items, and NPI caregiver distress total score) will be summarised by visit week and treatment group, using available observations in the *treatment period*. ADCS-CGIC will be summarised both as a continuous and as a categorical variable. Descriptive statistics for efficacy variables will be repeated by MMSE stratum.

Countries and sites where not all treatment groups are represented in the FAS will be grouped according to the specification in Section 18.6, and the grouped variable will be used in the efficacy analyses where site is included.

All the p-values will be based on two-sided tests; the confidence intervals (CIs) will be two-sided.

10.2 Analysis Methodology for the Primary Endpoint

10.2.1 Analysis of the Primary Endpoint

Changes from baseline in ADAS-Cog total score will be analysed using a restricted maximum likelihood (REML)-based mixed model for repeated measures (MMRM) approach. The model will include the fixed, categorical effects of treatment (placebo, idalopirdine 10mg, and idalopirdine 30mg), country, MMSE-stratum (<19, ≥ 19), and week (4, 12, and 24). Treatment-by-week interaction, and MMSE-stratum-by visit interaction will be included in the model as fixed effects. Baseline ADAS-Cog score and baseline score-by-week interaction will be included as continuous, fixed covariates.

An unstructured covariance structure will be used to model the within-patient errors. If this model fails to converge, the following covariance structures will be tested: first-order ante-dependence, heterogeneous compound symmetry, compound symmetry. The covariance structure converging to the best fit, as determined by Akaike's information criterion, will be used as the primary analysis. The Kenward-Roger approximation will be used to estimate denominator degrees of freedom. The analysis will be based on the missing-at-random (MAR) assumption and performed using all available observations (observed cases [OC] data) in the *treatment period*. The SAS code for the MMRM analysis is located in Appendix III.

The mean differences between each dose of idalopirdine (10 mg and 30 mg) and placebo will be estimated based on the least squares means for the treatment-by-visit interaction in the MMRM-model. The estimates will be presented with nominal p-values and 95% CIs. The primary comparisons will be the contrasts between each dose of idalopirdine (10 mg and 30 mg) and placebo at the 24-week visit. Details of the statistical testing for the primary endpoint are provided in section 10.4.

MMRM analysis pooling the 10 mg and 30 mg doses into one arm testing the effect of 10 mg and 30 mg pooled, versus placebo, will be performed on an exploratory basis.

10.2.2 Rationale for Selected Analysis Method for the Primary Endpoint

The MMRM analysis uses all available data measured repeatedly over time and allows for evaluation of the treatment-by-time interaction. The MMRM analysis provides an unbiased estimate of the treatment effect under the assumption that missing data are MAR.

Published data support the robustness of the MMRM analysis regarding protection against type I error and against bias, also in situations with a non-negligible proportion of missing data. Using extensive simulations, it has been demonstrated that the type I error is only affected to a limited extent and that the bias is small under the assumption that 1/3 of the missing data are missing-not-at-random, even when there is a severe imbalance between the treatment groups in the proportion of withdrawals.[1]

10.2.3 Subgroup Analyses and Model Assumptions for Analysis of the Primary Endpoint

A plot with mean values-by-week will be presented, grouped after withdrawal pattern (week of last available value). At or before last available week, the mean values will be the mean of observed (unadjusted) values. The mean values after last available week will be based on values predicted from the MMRM-model in paragraph 10.2.1. Solid lines will indicate observed pattern, and dotted lines will indicate predicted pattern. The plot will include information about the number of patients for each withdrawal pattern. The plot will also be generated separately for each primary reason for withdrawal.

Subgroups of special interest are (ranked in the listed order):

- MMSE stratum
- Apathy (yes/no), where apathy is defined as baseline NPI itemapathy score >0
- Age groups age<85 and age≥85

The assumption of equal treatment effect for the MMSE stratum will be investigated. Analyses will be performed for each stratum separately, using the same methodology as that described for the primary analysis (see Section 10.2.1) excluding MMSE stratum and MMSE stratum-by-visit interaction from the model.

The assumption of equal treatment effect for the MMSE stratum will also be investigated by adding the three way interaction MMSE stratum-by-treatment-by-week to the model in the

primary analysis (see section 10.2.1). The treatment effect for each dose of idalopirdine compared to placebo in each stratum will be estimated by least squares means for the contrast MMSE stratum-by-treatment-by-week interaction. The primary comparisons will be the contrasts between each dose of idalopirdine and placebo in each stratum at Week 24. The p-value for the test of equal treatment effect across the MMSE stratum for each dose of idalopirdine compared to placebo at week 24 will be presented.

The subgroup analysis of patients with or without apathy at baseline is to test if apathy may serve as a phenotypic marker for a cohort of patients with higher level of response. The analysis will be conducted as described for the MMSE stratum subgroup analysis.

Consistency of effect across age groups (<85 | ≥85) will also be performed with the corresponding analyses as for MMSE stratum.

10.2.4 Sensitivity Analyses of the Primary Endpoint

Sensitivity analyses will be performed to evaluate how different assumptions affect the estimates of the treatment effect.

The total number of patients with a value of the primary endpoint will be reported. In addition, the number of patients (of those having a value of the primary endpoint) who had a value included in the primary analysis, or a value collected in the withdrawal follow-up will be summarised.

Individual subject-by-time (actual time) plots of the primary variable by primary reason for withdrawal or completion will be presented, including follow-up efficacy data. Data captured in the *treatment period* will be indicated with solid lines, and data captured in the withdrawal follow-up period will be indicated with dashed lines. Time of first and last IMP intake will be marked in the plot.

The same MMRM analysis as that described for the primary endpoint in paragraph 10.2.1 including *follow-up efficacy data* for patients withdrawn from treatment will be done as a sensitivity analysis.

An analysis using a pattern-mixture model (PMM) will be performed, in which monotone missing values in patients withdrawn from treatment will be imputed using multiple imputation (MI) based on the placebo group.[2,3] The analysis will be based on the set of patients that are included in the primary analysis. The PMM assumes that the distribution for patients who withdraw from treatment is equal to the conditional distribution for the placebo group with the corresponding past. This is the basis for the multiple imputation of the monotone missing values in all treatment group. The PMM model will include country, MMSE stratum, baseline ADAS-Cog total score, and change from baseline in ADAS-Cog total score at week 4, 12, and 24.

To prepare data for the PMM, a dataset with only monotone missing values will be create, imputing non-monotone missing values by MI based on a Markov chain Monte Carlo (MCMC) model. The assumption in the MCMC model is that non-monotone missing values are missing at random. The MCMC analysis will be performed by treatment group and

MMSE stratum and the model will include baseline ADAS-Cog total score and change from baseline in ADAS-Cog total score at week 4, 12, and 24. In total, 200 simulations will be performed using randomo seeds 18253 (MCMC model) and 6483154 (PMM).

The 200 datasets will be analysed using the MMRM model specified in parapgraph 10.2.1. Monotone missing values in patients that are not withdrawn from treatment will be assumed to be MAR, and missing values imputed from the PMM in those patients will be re-set to missing before the MMRM-analysis. The estimated treatment effects and standard errors across the 200 simulations will be combined to produce a unique point estimate and standard error, taking into account the uncertainty of the imputation.[4] This approach will generally provide a conservative estimate of the treatment effect since it both penalises high withdrawal rates as well as higher withdrawal rates on the experimental therapy. The SAS code for the analysis included in Appendix III.

A plot with mean values-by-week will be presented, grouped by withdrawal pattern (week of last available value). At or before last available week, the mean values will be the mean of the observed (unadjusted) values. The mean values after last available week will be based on values imputed from the PMM (values for patients withdrawn from treatment) and values predicted from the MMRM model (values for patients not withdrawn from treatment). Solid lines will indicate observed pattern, and dotted lines will indicate imputed/predicted pattern. The plot will include information about the number of patients for each withdrawal pattern.

Modifications where only data missing due to adverse events (primary reason) are imputed using the same methodology (PMM) will also be performed (that is, data missing due to the other reasons for withdrawal [protocol violation, withdrawal of consent, and other reasons] will be assumed to be MAR.)

An analysis with country replaced by site will be performed for the model described in section 10.2.1.

An analysis will be performed with MMSE total score at baseline as a continuous covariate, and MMSE total score at baseline-by-week interaction added to the model described in section 10.2.1.

10.3 Analysis Methodology for the Key Secondary Endpoints

10.3.1 Analysis of the Key Secondary Endpoints

For the key secondary endpoints, ADCS-CGIC and ADCS-ADL_{23}, the same methodology as that described for the primary analysis (see section 10.2.1) will be used.

For ADCS-CGIC, the scores at each visit will be analysed as opposed to changes from baseline since the score itself is an assessment of change from baseline. The ADCS-CGIC score at baseline, which is a clinical status evaluation, will be included for covariate adjustment, however.

The testing strategy for the key secondary endpoints is described in section 10.4.

10.3.2 Rationale for Selected Analysis Method for the Key Secondary Endpoints

The rationale is the same as described for the primary endpoint, see section 10.2.2.

10.3.3 Subgroup Analyses and Model Assumptions for Analysis of the Key Secondary Endpoints

Investigation of the robustness of the model assumptions and consistency of treatment effect across subgroups will be performed in the corresponding way as for the primary endpoint, see section 10.2.3.

10.3.4 Sensitivity Analyses of the Key Secondary Endpoints

The corresponding sensitivity analyses as for the primary endpoint (see section 10.2.4) will be applied for the key secondary endpoints.

In addition, for ADCS-CGIC at week 24, a logistic regression model for ordinal response will be applied to explore sensitivity to the normal distribution assumption for this variable in the primary analysis. The model will include treatment as a factor and baseline score as a covariate. The possible responses are {1,2,3,4,5,6,7}. Because the extreme categories are rare the responses will be grouped as {(1,2),3,4,5,(6,7)}. The analysis will be based on observed cases, using a logit link function to relate the underlying latent variable to the probability of observing a response less than or equal to a given ordered response.

Likelihood-ratio statistics and corresponding p-values for the dose effects at week 24 will be derived from the maximum likelihood estimates and standard errors of the regression parameters for the two doses versus placebo at week 24. The estimates will also be reported as odds ratios (versus placebo) of response.

10.4 Testing Strategy

Efficacy of the doses will be tested in a gated approach. The 30 mg dose is tested at a 5% level of significance and only if this dose is found efficacious, the testing will proceed to the 10 mg dose. The test procedure, a sequentially-rejective, weighted Bonferroni multiple test procedure controlling overall type I error is illustrated using the graphical approach of Bretz et al[5] in Panel 3. Hochberg's method of adjustment will be applied at the bottom of the hierarchy.

A summary table for the primary and key secondary endpoints will be presented with the estimated treatment differences, nominal p-values, and multiplicity-adjusted p-values (i.e. the significance level under which the dose would meet the efficacy criterion based on the testing strategy).

Panel 3 Sequentially Rejective Multiple Test Procedure



The graph nodes indicate hypotheses to be tested. For example the box labelled ADAS-Cog30mg corresponds to the null hypothesis of no difference between 30mg and placebo in mean ADAS-Cog change at Week 24. The arrows with weights indicate how the testing will proced and the α will be redistributed from the current test if significant. Hochberg's method will be applied at the bottom of the hierarchy to adjust for multiplicty between the two key secondary endpoints, ADCS-CGIC and ADCS-ADL_{23} for the 10mg dose. This test will be performed at the same level as the test for ADAS-Cog for 10mg according to the re-distribution of α down the hierarchy.

10.5 Analysis of the Secondary Endpoints

Changes from baseline in NPI total score, changes from baseline in individual NPI items, changes from baseline in NPI total caregiver distress, composite score and ADAS-Cog and ADCS-ADL_{23}, changes from baseline in ADL-B and changes from baseline in ADL-I at week 4, 12, and 24 will be analysed using the same methodology as that described for the primary endpoint (see section 10.2.1). Changes from baseline in NPI single items at Week 4, 12, and 24 in the subset of patients with an item score of at least 2 at baseline will also be analysed using the same methodology as that described for the primary endpoint.

Emergence of individual NPI items (score≥3) at Week 24 for the subset of patients with an item score of <3 at baseline will be compared for each dose versus placebo using a Cochran-Mantel-Haenszel (CMH) test for comparing the proportion of patients with emerging symptoms stratifying for country and MMSE stratum using observed cases.

The proportion of patients with clinical response (defined as ΔADAS-Cog ≤ -4 and ΔADCS-ADL_{23} ≥ 0 and ADCS-CGIC ≤ 4) at Week 24 will be compared for each dose of idalopirdine versus placebo using a Cochran-Mantel-Haenszel test stratifying for country and MMSE stratum. The analysis will be done for observed cases, as well as by imputing missing values as non-response (NR). The corresponding analyses will be performed for the proportion of patients with response, where response is defined using cut-offs of ≤-3, ≤-2 , and ≤-1 for

ADAS-Cog change and no deterioration in ADCS-ADL_{23} or ADCS-CGIC (ADCS-ADL_{23} change ≥0 and ADCS-CGIC≤4).

The proportion of patients with clinical worsening (defined as ΔADAS-Cog ≥ 4 and ΔADCS-ADL_{23} < 0 and ADCS-CGIC > 4) at Week 24 will be compared for each dose of idalopirdine versus placebo using a Cochran-Mantel-Haenszel test stratifying for country and MMSE stratum. The analysis will be done for observed cases, as well as by imputing missing values as clinical worsening.

Changes from baseline in MMSE score (ΔMMSE) at Week 24 will be analysed using an ANCOVA model with treatment, country, and MMSE stratum as fixed factors and baseline MMSE score as covariate using observed cases.

AUC from baseline to Week 24 for the changes from baseline in ADAS-Cog total score, changes from baseline in ADCS-ADL_{23} total score, and ADCS-CGIC minus 4 will be calculated by applying the trapezoidal rule to the least square mean estimates based on the same model as in the primary analysis (see paragraph 10.2.1)[6]. The cumulative treatment effects compared to placebo based on the AUC estimates will also be calculated.

Analyses of EQ-5D utility score and EQ-5D VAS are described in section 13.

All analyses will be repeated by MMSE stratum.

11 Safety

11.1 Adverse Events

11.1.1 General Methodology for Adverse Events

Unless otherwise specified, tables, graphs, and listings will be based on the APTS.

All the tables and graphs will be presented by treatment group.

Tables by preferred term and tables by system organ class (SOC) and preferred term will be sorted in descending order by the percentage of patients in the highest dose group of idalopirdine (30 mg).

Unless otherwise specified, the summaries of adverse events will include the total number and percentage of patients with an adverse event. Tables by preferred term and tables by SOC and preferred term will also include information about the total number of events. For sex-specific preferred terms, the denominator in the % calculations will be the number of patients of that sex. Sex-specific preferred terms will be marked in the summaries.

In summaries of adverse events presented by intensity, the maximum intensity of the adverse event will be used for patients who have more than one intensity of that event. Adverse events for which information on intensity is missing will be classified as *severe*.

Listings of adverse events will be sorted by treatment group, site, patient screening number, and adverse event start date and include preferred term, investigator term, adverse event start date, days since first dose of IMP, duration of the adverse event, date of death, action taken, causality, intensity, seriousness, and outcome. For adverse events that change in intensity, each intensity will be included.

11.1.2 Coding of Adverse Events

Adverse events will be coded using MedDRA, Version 17.1, or later.

11.1.3 Classification of Adverse Events

Adverse events will be classified according to the time of onset of the adverse event:

- *pre-treatment adverse event* – an adverse event that starts at or prior to the date of first dose of IMP
- *treatment-emergent adverse event* (TEAE) – an adverse event that starts or increases in intensity at or after the date of first dose of IMP and for which *causality to IMP* not recorded as *Not Related – Prior to IMP*

For handling of missing or incomplete dates in the classification of adverse events, see sections 18.4.1 (IMP start date) and 18.4.6 (adverse event start or stop dates).

An adverse event is considered causally related to the use of the IMP when the causality assessment by the investigator is *probable* or *possible.*

11.1.4 All Adverse Events

All adverse events will be listed for the APRS.

An overview of the PYE to IMP (see definition in Section 9), numbers, and percentages of patients with TEAEs, serious adverse events (SAEs), adverse events leading to withdrawal, or who died will be provided based on the APTS. For TEAEs, SAEs, and adverse events leading to withdrawal, the total number of events will be included.

11.1.5 Pre-treatment Adverse Events

Pre-treatment adverse events will be summarised by preferred term.

11.1.6 Treatment-emergent Adverse Events

The following summaries will be provided:

- TEAEs by SOC and preferred term
- TEAEs by preferred term
- TEAEs with an incidence >5% in any treatment group by preferred term
- causally related TEAEs by SOC and preferred term

- TEAEs by intensity (*mild*/*moderate*/*severe*), and preferred term
- causally related TEAEs by intensity, and preferred term

The summary of TEAEs by SOC and preferred term will also be done by MMSE stratum.

11.1.7 Deaths

All adverse events with outcome death will be summarised.

All adverse events for patients who died will be listed.

11.1.8 Serious Adverse Events

All SAEs will be listed. SAEs occurring after the Completion/Withdrawal Visit will also be listed separately.

Treatment-emergent SAEs will be summarised by:
- SOC and preferred term
- preferred term

11.1.9 Adverse Events Leading to Withdrawal

All adverse events leading to withdrawal will be listed.

TEAEs leading to withdrawal will be summarised by:
- SOC and preferred term
- preferred term

11.1.10 Adverse Events of Special Interest

The following SMQs will be summarised in total and by preferred term:
  - Convulsions (narrow scope)
  - Drug related hepatic disorders (comprehensive search)
  - Haemorrhages (broad scope)

Individual subject plots with the duration of each event during the *treatment period* for the preferred terms diarrhoea, vomiting, and nausea will be presented. Intensity (mild, moderate, and severe) will be indicated by different grey colours, and first and last IMP intake will be marked in plots.

11.2 General Methodology for Other Safety Data

Unless otherwise specified, tables, graphs, and listings will be based on the APTS.

All the tables and graphs will be presented by treatment group.

The denominators for the summaries of a given variable will be based on the number of patients with non-missing values at a given visit or during the assessment period.

Descriptive statistics for the safety variables (lab tests, vital signs, weight, and ECGs), both absolute values and changes from baseline will be presented by visit week and the last assessment. All available assessments will be included in the identification of the last assessment (scheduled, re-assessments, and unscheduled).

The number and percentage of patients with at least one PCS value at any post-baseline assessment time point will be summarised by variable. All available assessments will be included in the evaluation of PCS values (scheduled, re-assessments, and unscheduled).

The number and percentage of patients with out-of-reference range values and PCS values will be summarised by variable, and by visit week and last assessment.

For details about data handling issues, see sections 18.1 and 18.3.2.

For patients with post-baseline PCS values, listings will be provided including all available values for the variable, with flagging of PCS values and out-of-reference-range values.

All adverse events for patients with PCS values will be listed by treatment group and patient screening number and include the PCS value; investigator term and preferred term for the adverse event; and intensity, seriousness, causality, action taken, outcome, start date, and duration of the adverse event, and days since first dose of IMP. The PCS value will be listed next to the corresponding adverse event(s); the PCS values and adverse events will be listed in chronological order according to assessment date and the start date of the adverse event.

For selected variables, the following graphical presentations will be provided:

- box plots by visit and the last assessment
- patient line plots with all available assessments. If relevant, out-of-reference-range and/or PCS values will be marked in the plot. Reference lines for reference ranges and/or PCS limits may also be included. If more than one value is available at a given assessment time point, the most severe value will be used in the plots (maximum or minimum).

11.3 Clinical Safety Laboratory Test Data

11.3.1 Data Presentation

The PCS criteria for the clinical safety laboratory tests are described in Table 2.

All the clinical safety laboratory test values will be presented in conventional and/or Système International (SI) units.

The summary statistics for GGT, ALT, AST, ALP, BILI, and EOSLE will be presented in a separate table, also including worst (highest) post-baseline assessment. All available assessments will be included in the evaluation of the worst assessment (scheduled, re-assessments, and unscheduled).

Graphical presentations of gamma glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total serum bilirubin (BILI) are described in Panel 4 (further graphical presentations of ALT, AST, ALP, and BILI will be done in the evaluation of drug-induced liver injury, see paragraph 11.3.3). The graphs will be presented by treatment group and sex.

If relevant, shift tables will be presented for select safety variables.

Panel 4 Graphical Presentations for the Clinical Safety Laboratory Tests

Laboratory Test	Measure	Patient Selection	Line Plot	Box Plot
GGT, ALT, AST, AP and total bilirubin	Absolute measure			√
GGT	Absolute measure	Patients with at least one post-baseline value out of upper reference range for GGT	√	
ALT	Absolute measure	Patients with at least one post-baseline value out of upper reference range for ALT	√	
AST	Absolute measure	Patients with at least one post-baseline value out of upper reference range for AST	√	
AP	Absolute measure	Patients with at least one post-baseline value out of upper reference range for AP	√	
Total bilirubin	Absolute measure	Patients with at least one post-baseline value out of upper reference range for total bilirubin	√	

11.3.2 Urinalysis

For tests based on urine dipsticks, for which the results are categorical, the number and percentage of patients will be summarised for each test by visit week and last assessment.

The microscopy results will be listed for patients with any positive urine tests by assessment time point.

11.3.3 Evaluation of Potential Drug-induced Liver Injury (DILI)

Signals of DILI will be assessed according to the FDA guideline.[7]

Number and percentage of patients post-baseline in the categories below for AST/ALT and AST and ALT separately will be summarised:

- ULN < value ≤ 1.5xULN

- 1.5xULN < value ≤ 2xULN
- 2xULN < value ≤ 3xULN
- 3xULN < value ≤ 5xULN
- 5xULN < value ≤ 10xULN
- 10xULN < value ≤ 20xULN
- 20xULN < value

Number and percentage of patients post-baseline in the categories below for ALP and BILI separately will be summarised:

- ULN < value ≤ 1.5xULN
- 1.5xULN < value ≤ 2xULN
- 2xULN < value ≤ 3xULN
- Value > 3xULN

The cumulative number and percentage of patients in the categories post-baseline will also be summarised.

In the summaries, each patient should be counted only once using the worst post-baseline assessment.

Number and percentage of patients fulfilling the join criteria below post-baseline will be summarised:

- (PEAK ALT or PEAK AST > 3×ULN) AND PEAK BILI > 2xULN and PEAK ALP > 1.5xULN
- (PEAK ALT or PEAK AST > 3×ULN) AND PEAK BILI > 2xULN and PEAK ALP ≤ 1.5xULN
- PEAK GGT > 200 (IU/L) without (PEAK ALT or PEAK AST or PEAK ALP > 2xULN)

Number and percentage of patients with a post-baseline value ≥50% for B-eosinophils/leukocytes (ESOLE) will be summaries.

Evaluation of potential Drug-Induced Serious Hepatoxicity (eDISH) will also be done by plots. Scatter plots of peak ALT/AST versus peak BILI (note that this means that the peak ALT/AST and the peak BILI may not occur at the same assessment time-point). The values will be normalised by ULN (unit x ULN) and the X and Y-axes will be on the log scale. The plot will include a reference line for ALT/AST values >3xULN, and a reference line for BILI values > 2xULN. Four quadrants are defined by the reference lines, where the right upper quadrant being the most specific indicator for a drug's potential for causing serious liver injury (Hy's law quadrant). The plot will include the number of patients in each quadrant for each treatment group.

Subject line plots with values by time for ALT, AST, ALP, BILI,EOSLE, and GGT (overlaid in the same plot) will be generated for patients with ALT/AST > 1xULN. The test values will be normalised by the ULN (unit x ULN) and the Y-axis will be on the log scale. The time will be days since baseline, and reference lines for the day of first and last IMP intake will be

included. All assessments will be included. If there is more than one assessment at the same time point for a test, the maximum value will be used.

Conditional correlations of values adjusted for patient level (mean value for each subject's entire treatment period subtracted from the subject values at each visit) of ALT, AST, ALP, and BILI versus EOSLE will be generated at tables and scatter plots for:

- All patients
- Patients with a post-baseline value of ALT/AST > 2xULN
- Patients with a post-baseline value of ALT/AST > 3xULN

Patients with a post-baseline value of GGT, ALT, AST, ALP, BILI or IOSLE > 1xULN will be listed, and the listing will include all available ALT, AST, BILI, ALP, GGT, and EOSLE values, sorted by site, treatment group, subject number, assessment date and time.

11.4 Vital Signs and Weight

The PCS criteria for vital signs and weight are in

Table 3.

The box plot for BMI will include a reference line for underweight (BMI<18.5 kg/m^2) and overweight (BM>30).

An overview of the graphical presentations for vital signs and weight is provided in Panel 5.

Panel 5 Graphical Presentations for Vital Signs and Weight

Variable	Measure	Patient Selection	Line Plot	Box Plot
Standing systolic BP	Absolute value			√
Standing diastolic BP	Absolute value			√
Standing pulse rate	Absolute value			√
Sitting systolic BP	Absolute value			√
Sitting diastolic BP	Absolute value			√
Sitting pulse rate	Absolute value			√
Weight	Percentage change from baseline	Patients with a post-baseline PCS value	√	
BMI	Absolute value			√

11.5 ECGs

The PCS criteria for the ECG parameters are in

Table 4.

An overview of the graphical presentations for ECGs is provided in Panel 6.

Panel 6 Graphical Presentations for ECG Parameters

Variable	Measure	Patient Selection	Line Plot	Box Plot
Heart rate	Absolute value			√
QTcB	Absolute value			√
ΔQTcB	Change from baseline	Patients with post-baseline PCS value	√	
QTcF	Absolute value			√
ΔQTcF	Change from baseline	Patients with post-baseline PCS value	√	

11.6 Neurological Examinations

Shift tables for neurological examination findings displaying shifts from baseline to the Completion/Withdrawal Visit will be provided for each examination and combination and include the numbers and percentages of patients.

11.7 Other Safety Endpoint

11.7.1 Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS was assessed:

- for lifetime (using the Baseline Version) – the C-SSRS assessment obtained at screening visit that collects a lifetime recall
- at baseline and post-baseline (Visit 3 to Visit 7) using the Since Last Visit Version

The summaries will be based on the APTS by treatment group for patients with at least one post-baseline C-SSRS assessment, regardless of whether they had a baseline C-SSRS assessment.

Missing C-SSRS scores will not be imputed.

The C-SSRS items are described in Panel 7. Patients with *no suicidal ideation or behaviour* are those who answered "No" to all items for *suicidal ideation* and *suicidal behaviour*. For each evaluation (lifetime, baseline, and post-baseline), the most severe event per patients related to *suicidal ideation* and *suicidal behaviour* will be summarised.

In the C-SSRS, *non-suicidal self-injurious behaviour* is captured as a different behaviour, and regarded independently of reported *suicidal ideation* and *suicidal behaviour* events.

Positive responses to *non-suicidal self-injurious behaviour* will be summarised for each evaluation (lifetime, baseline, and post-baseline).

Panel 7 C-SSRS Items

eCRF Item	Description
	Patients who answered 'No' to all items in Suicidal Ideation and Suicidal Behaviour
	Suicidal Ideation
CSSRS01	Wish to be dead
CSSRS02	Non-specific active suicidal thoughts
CSSRS03	Active suicidal ideation with any methods (not plan) without intent to act
CSSRS04	Active suicidal ideation with some intent to act, without specific plan
CSSRS05	Active suicidal ideation with specific plan and intent
	Suicidal Behaviour
CSSRS25	Preparatory acts or behaviour
CSSRS23	Aborted attempt
CSSRS21	Interrupted attempt
CSSRS18	Non-fatal suicide attempt
CSSRS27	Completed suicide (only applicable for the post-baseline assessments)
	Self-Injurious Behaviour Without Suicidal Intent
CSSRS20	Non-suicidal, self-injurious behaviour

For patients with any post-baseline *suicidal behaviour* (C-SSRS scores of 6 to 10), listings will be prepared including all C-SSRS scores; C-SSRS scores related to *suicidal behaviour* will be flagged.

12 Pharmacokinetic and Pharmacodynamic Analyses

Plasma concentrations of both idalopirdine and donepezil will be summarised by descriptive statistics by treatment group and visit.

A separate analysis plan describing the non-linear mixed effect modelling in more detail will be prepared by H. Lundbeck A/S: Department of Quantitative Pharmacology in collaboration with the Biostatistics Department and the results reported separately but referred to in the *Clinical Study Report*, as relevant.

13 Pharmacoeconomic Analyses

Dependence level score (based on the Dependence scale, see paragraph 18.2.8) will be summarised both as a continuous and as a categorical variable. Absolute values and change from baseline values in EQ-5D utility score, EQ-5D VAS, dependence level score, and dependence total score (based on the Dependence scale, see paragraph 18.2.8) will be summarised by visit week and treatment group. Absolute values and shift from baseline in equivalent institutional care (dependence scale) will be summarised by visit week and

treatment group. Note that the dependence scale was added as a pharmacoeconomic assessment in protocol amendment.

The RUD Lite items will be summarised by visit week and treatment group.

Changes from baseline in EQ-5D utility score and EQ-5D VAS at week 12 and 24 will be analysed using the same methodology as that described for the primary endpoint (see section 10.2.1).

Increase from baseline in dependence level score will be defined as a binary variable (1 if change from baseline in dependence level score>0, and 0 if change from baseline in dependence level score <0) at week 12 and 24, and compared for each dose versus placebo using a Cochran-Mantel-Haenszel test stratifying for country and MMSE stratum. The analysis will be done for observed cases.

All analyses will be repeated by MMSE stratum.

Further presentations and statistical analyses of pharmaco-economics will be detailed in a separate Pharmaco-Economic Statistical Analysis Plan, prepared by the Global Analytics Department, H. Lundbeck A/S, prior to unblinding. The results of the pharmaco-economic analyses described in the Pharmaco-Economic SAP will be presented in a separate pharmacoeconomic report.

14 Interim Analyses

No interim analyses of efficacy are planned. An independent Data Monitoring Committee (DMC) has carried out monitoring of the safety data at regular intervals specified in the DMC Charter.

15 Sample Size Considerations

In total, 840 patients will be randomized 1:1:1 to idalopirdine 10 mg : 30 mg : placebo, providing a power of 80% for at least 30 mg dose showing significant improvements on an overall 5% level on both ADAS-Cog and at least one of ADCS-ADL_{23} or ADCS-CGIC, assuming mean improvements of 2 points on both ADAS-Cog and ADCS-ADL_{23}, and 0.25 and ADCS-CGIC for the 30 mg dose. The standard deviations (SDs) are approximately 6.10, 9.15, and 1.5 for the three outcomes when adjusting for intra-patient correlation and drop-out. The SD for each endpoint is obtained from the number of patients randomised in each arm (N1 and N2) and the standard error (SE) of the treatment effect estimate of 24 weeks in 12936A, phase II proof of concept study, as $SD=SE/\sqrt{(1/N1 +1/N2)}$. This estimate both takes into account the actual variance at 24 weeks and the loss of information due to drop-out during the study, assuming that the dropout pattern observed in 12936A is representative of what will be observed in this study. The estimated correlations between the endpoints are -0.27 between ADAS-Cog and ADCS-ADL_{23}, 0.38 between ADAS-Cog and ADCS-CGIC, and -0.35 between ADC-ADL23 and ADCS-CGIC when adjusting for baseline scores.

Multiplicity due to multiple doses and endpoints is adjusted for as explained in section 17.8.3 of the protocol. The power has been evaluated by simulation from a multivariate normal distribution with the assumed mean and covariance structure described.

16 Data and Analysis Standards and Statistical Software

The data will be collected and analysed in accordance with the Lundbeck standards specified in Lundbeck SDTM, Version 2.2 or later, SADs, Version 5.1 or later, and TGML, Version 7.0 or later.

The statistical software used will be SAS®, Version 9.4 or later.

17 Changes to Analyses Specified in the Protocol

The following endpoints were added:

Endpoints addressing the secondary objective:

- Change from baseline to Week 24 in NPI single items in patients with an item score of at least 2 at baseline
- Change from baseline in NPI caregiver distress total score

Endpoints that are supportive of the primary objective:

- Clinical response at Week 24 ([ΔADAS-Cog ≤ -3 or ΔADAS-Cog ≤ -2 or ΔADAS-Cog ≤ -1] and ADCS-ADL_{23} change ≥0 and ADCS-CGIC≤4)
- Area under curve (AUC) from baseline to week 24 for the changes from baseline in ADAS-Cog total score
- AUC from baseline to week 24 for the ADCS-CGIC minus four (as ADCS-CGIC is an assessment of changes, i.e. no change in health state corresponds to a score of 0)
- Composite score at Week 24 for ADAS-Cog and ADCS-ADL_{23}.
- Change from baseline to Week 24 in Basic Activities of Daily Living (ADL-B)
- Change from baseline to Week 24 in Instrumental Activities of Daily Living (ADL-I)

Note that the endpoint *Change from baseline to Week 24 in NPI Anxiety item score in patients with an NPI Anxiety score of at least 2 at baseline* in the protocol is included in *Change from baseline to Week 24 in NPI single items in patients with an item score of at least 2 at baseline.*

Analyses of the added endpoints are described in paragraph 10.5.

The endpoint *Emergence of individual NPI items (score>0)* for patients with an item score of 0 at baseline was replaced by:

- Emergence of individual NPI items (score ≥ 3). The analysis will be based on patients with an item score of <3 at baseline.

All CIs will be presented at the 95% confidence level.

Sensitivity analyses with country replaced by grouped site in the primary analysis of the primary and key secondary endpoints were added. (see paragraph 10.2.4 and 10.3.4).

Sensitivity analyses with MMSE as a continuous covariate, and MMSE total score at baseline-by-week interaction also included in the primary model were added for the primary and key secondary endpoints. (see paragraph 10.2.4 and 10.3.4).

A pooled analysis of the two doses vs. placebo was added and is described in section 10.2.1.

Subgroup analyses of apathy (yes/no), where apathy is defined as NPI item apathy score>0 at baseline, and age (< 85 and ≥85) were added for the primary and key secondary endpoints (see paragraph 10.2.3 and 10.3.3).

Instead of the specification of the model for the non-linear mixed model for ordinal response, a logistic regression analysis for the outcome at week 24 was specified as a sensitive analysis for ADCS-CGIC. This was due to technical challenges anticipated with fitting the non-linear mixed model for the repeated measures and imposed restrictions on the marginal correlation structure for these with this approach. In addition, the projected relative low withdrawal rate justifies the use of the simpler logistic model for observed cases at week 24 for sensitivity analysis. The model will use a logit link function to relate the underlying latent variable to the probability of observing a response less than or equal to a given ordered response (see paragraph 10.3.4).

18 Details on Data Handling

18.1 Definition of Baseline

The baseline value will be defined as the value captured either at the Screening Visit or at the Baseline Visit, whichever comes later.

18.2 Derived Variables

18.2.1 Mini-Mental State Examination (MMSE) Total Score and MMSE Stratum

MMSE consists of 8 subcategories (orientation to time, orientation to place, registration, attention and calculation, recall, language, repetition, and complex commands). In total there are 30 questions with correct/incorrect responses coded as 1/0. The MMSE total score is defined as the sum of the 30 questions. The total score ranges from 0 to 30 (at screening, the total score will range from 12 to 22 due to inclusion criteria restrictions). Lower scores indicate more severe dementia.

The subcategory *attention and calculation* consists of 5 questions (aCRF items MMSE04A to MMSE04E), where the patient continuously should subtract 7 from 100 (correct responses: 93, 86, 79, 72, and 65). If a question is answered incorrectly and the subsequent questions are not recorded, the missing responses will be counted as incorrect (0).

The total score will be missing if three or more item scores are missing. If less than three item scores are missing then the missing item scores will be imputed by the worst case (0).

MMSE stratum (mild, MMSE total score <19; moderate, MMSE total score ≥ 19) will be based on the assessment collected at the screening visit.

18.2.2 Alzheimer's Disease Assessment Scale – Cognitive Sub-scale (ADAS-Cog) Total Score

The ADAS-Cog assesses the patient's orientation, memory (word recall, recognition, and remembering instructions), language (spoken language ability, comprehension of the spoken language, word finding difficulty, naming objects and fingers, following commands), and praxis (ideational and constructional). The total score of the 11 items described in Panel 8. If three or more item scores are missing, the total score will be missing. If less than three item scores are missing, the missing item scores will be imputed by the worst score for the item.

The ADAS-Cog total score ranges from 0 to 70, with a lower score indicating a lower cognitive impairment.

Panel 8 Definition of ADAS-Cog Item Scores

ADAS-Cog Items	Data collected in the eCRF (aCRF variable name)	Definition of ADAS-Cog Item Scores used in the calculation of the total score (SADs paramcd name)
1. Word recall task	Total number of words recalled **correctly,** recorded in three trials (ranges 0-10 in each trial): ACOG01A (aCRF ADCOG01) ACOG01B (aCRF ADCOG02) ACOG01C (aCRF ADCOG03)	Average of the total number of words recorded incorrectly in the three trials rounded to the closest integer with 0.5 decimals rounded upwards (ranges from 0-10): ACITM01= round(((10- ADCRLT01)+(10- ADCRLT02)+(10- ADCRLT03))/3,1.); If <3 of the eCRF scores are missing, the item score will be the average of the available scores.
2. Naming objects and fingers	Total number of object/fingers named **correctly** (ranges 0-17): ACOG02 (aCRF ADCOG05)	eCRF score converted to total number of object/fingers named incorrectly (17-ADCOF), and then classified according to the scoring scheme below (ranges 0-5): ACITM02= 0 = 0 – 2 1 = 3 – 5 2 = 6 – 8 3 = 9 – 11 4 = 12 – 14 5 = 15 – 17.
3. Commands	Total number of commands performed **correctly** (ranges 0 – 5): ACOG03 (aCRF ADCOG07)	eCRF score converted to total number of commands performed incorrectly (ranges 0-5): ACITM03=5- ACOG03;
4. Constructional praxis[a]	Total number of drawings performed **incorrectly** (ranges 0 – 5): ACOG04 (aCRF ADCOG08)	ACITM04
5. Ideational praxis	Total number of steps completed **correctly** (ranges 0 -5): ACOG05 (aCRF ADCOG09)	eCRF score converted to total number of steps completed incorrectly (ranges 0-5): ACITM05=5- ACOG05;
6. Orientation	Total number of items answered **correctly** (ranges 0 – 8): ACOG06 (aCRF ADCOG10)	eCRF score converted to total number of items answered incorrectly (ranges 0-8): ACITM06=8-ACOG06;
7. Word recognition task	Total number of words identified **correctly** and total number of words identified **incorrectly** (both scores range 0 – 12): ACOG07A (aCRF ADCOG11) ACOG07B (aCRF ADCOG12)	Total number of words identified **incorrectly**, where scores>12 truncated to 12 (ranges 0-12): ACITM07= Min((12- ADCRGT01)+ ADCRGT02, 12);

		If ADCRGT01 or ADCRGT02 is missing, the item score will be missing.
8. Remembering test instructions	Level of impairment (ranges 0-5, see category labels below): ACOG08 (aCRF ADCOG14) 0 = None 1 = Very Mild 2 = Mild 3 = Moderate 4 = Moderately Severe 5 = Severe	ACITM08
9. Language	Level of impairment (ranges 0-5, same category labels as for item 9): ACOG09 (aCRF ADCOG15)	ACITM09
10. Comprehension of spoken language	Level of impairment (ranges 0-5, same category labels as for item 8): ACOG10 (aCRF ADCOG16)	ACITM10
11. Word finding difficulty	Level of impairment (ranges 0-5, same category labels as for item 8): ACOG11 (aCRF ADCOG17)	ACITM11

18.2.3 Alzheimer's Disease Co-operative Society – Activities of Daily Living (ADCS-ADL$_{23}$) Total Score

The ADCS-ADL$_{23}$ consists of 23 single item scores (Usual Eating Performance, Optimal Walking Performance, Usual Bowel/Bladder Function, Usual Bathing Performance, Optimal Grooming Performance, Dressing, Use a Telephone, Watch Television, Pay Attention to Conversation, Clear Dishes, Find Belongings, Obtain Beverage, Make a Meal, Dispose of Garbage, Get Around Outside Home, Go Shopping, Keep Appointments, Left On His/Her Own, Talk About Current Events, Read More Than 5 Minutes, Write Things Down, Perform Pastime, and Use Household Appliance), where each item contains one or more questions.

The ADCS-ADL$_{23}$ total score is defined as the sum of the 23 item scores.

"Don't know" responses will be counted as worst case (0). For patients institutionalized, the item score number 18 (Left on his/her own) will be counted as worst case (0). For institutionalized patients, item score number 18 (Left on his/her own) will be counted as worst case (0). The scoring scheme for the item scores are described in Panel 9.

Panel 9 Definition of ADCS-ADL$_{23}$ Item Scores

ADCS-ADL$_{23}$ Item	**Data collected in the eCRF (aCRF variable name)**	**Defintion of ADCS-ADL$_{23}$ Item Scores used in the calculation of the total score (SADs paramcd name)**
1. Usual Eating Performance	ADADL01	Item score ranges 0-3: ADL01=ADADL01
2. Optimal Walking Performance	ADADL02	Item score ranges 0-3: ADL02=ADADL02
3. Usual Bowel/Bladder Function	ADADL03	Item score ranges 0-3: ADL03=ADADL03
4. Usual Bathing Performance	ADADL04	Item score ranges 0-3: ADL04=ADADL04
5. Optimal Grooming Performance	ADADL05	Item score ranges 0-3: ADL05=ADADL05
6. Dressing	ADADL06 ADADL07 ADADL08	Item score ranges 0-7: If ADADL06=”No” or ADADL06= “Don’t know” then ADL06=0; else if ADADL06= “Yes” then ADL06= ADADL07; ADL06=ADL06+ADADL08;
7. Use a Telephone	ADADL09 ADADL10	Item score ranges 0-5: If ADADL09= “No” or ADADL09=”Don’t know” then ADL07=0; else if ADADL09= “Yes” then ADL07= ADADL10;
8. Watch Television	ADADL11 ADADL12 ADADL13 ADADL14	Item score ranges 0-3: if ADADL11= “No” or ADADL11= “Don’t know” then ADL08=0; %** “Yes”/ “No”/ “Don’t know” counted as 1/0/0; else if ADADL11= “Yes” then ADL08= ADADL12+ADADL13+ ADADL14;
9. Pay Attention to Conversation	ADADL15 ADADL16	Item score ranges 0-3: If ADADL15= “No” or ADADL15 “Don’t know” then ADL09=0; else if ADADL15= “Yes” then ADL09= ADADL16;

10. Clear Dishes	ADADL17 ADADL18	Item score ranges 0-3: If ADADL17= “No” or ADADL17= “Don’t know” then ADL10=0; else if ADADL17= “Yes” then ADL10= ADADL18;
11. Find Belongings	ADADL19 ADADL20	Item score ranges 0-3: If ADADL19= “No” or ADADL19= “Don’t know” then ADL11=0; else if ADADL19= “Yes” then ADL11= ADADL20;
12. Obtain Beverage	ADADL21 ADADL22	Item score ranges 0-3: If ADADL21= “No” or ADADL21= “Don’t know” then ADL12=0; else if ADADL21= “Yes” then ADL12= ADADL22;
13. Make a Meal	ADADL23 ADADL24	Item score ranges 0-4: If ADADL23= “No” or ADADL23= “Don’t know” then ADL13=0; else if ADADL23= “Yes” then ADL13= ADADL24;
14. Dispose of Garbage	ADADL25 ADADL26	Item score ranges 0-3: If ADADL25= “No” or ADADL25= “Don’t know” then TADL14=0; else if ADADL25= “Yes” then ADL14= ADADL26;
15. Get Around Outside Home	ADADL27 ADADL28	Item score ranges 0-4: If ADADL27= “No” or ADADL27= “Don’t know” then ADL15=0; else if ADADL27=”Yes” then ADL15= ADADL28;
16. Go Shopping	ADADL29 ADADL30 ADADL31	Item score ranges 0-4: If ADADL29= “No” or ADADL29= “Don’t know” then ADL16=0; %**“Yes”/ “No”/ “Don’t know” counted as 1/0/0 (ADADL31); else if ADADL29= “Yes” then ADL16= ADADL30+ ADADL31;
17. Keep Appointments	ADADL32 ADADL33	Item score ranges 0-3: If ADADL32= “No” or ADADL32= “Don’t know” then ADL17=0; else if ADADL32= “Yes” then ADL17= ADADL33;

18. Left On His/Her Own	ADADL34 ADADL35 ADADL36 ADADL37 ADADL38	Item score ranges 0-3: If ADADL34= “Checked” then ADL18=0; else if ADADL35= “No” or ADADL35= “Don’t know” then ADL18=0; %**“Yes”/ “No”/ “Don’t know” counted as 1/0/0; else if ADADL35= “Yes” then ADL18= ADADL36+ ADADL37+ ADADL38;
19. Talk About Current Events	ADADL39 ADADL40 ADADL41 ADADL42	Item score ranges 0-3: if ADADL39= “No” or ADADL39= “Don’t know” then ADL19=0; %**“Yes”/ “No”/ “Don’t know” counted as 1/0/0; else if ADADL39= “Yes” then ADL19= ADADL40+ ADADL41+ ADADL42;
20. Read More Than 5 Minutes	ADADL43 ADADL44 ADADL45	Item score ranges 0-2: if ADADL43= “No” or ADADL43= “Don’t know” then ADL20=0; %**“Yes”/ “No”/ “Don’t know” counted as 1/0/0; else if ADADL43= “Yes” then ADL20= ADADL44+ ADADL45;
21. Write Things Down	ADADL46 ADADL47	Item score ranges 0-3: If ADADL46= “No” or ADADL46= “Don’t know” then ADL21=0; else if ADADL46= “Yes” then ADL21= ADADL47;
22. Perform Pastime	ADADL48 ADADL49	Item score ranges 0-3: If ADADL48= “No” or ADADL48= “Don’t know” then ADL22=0; else if ADADL48= “Yes” then ADL22= ADADL49;
23. Use Household Appliance	ADADL50 ADADL51	Item score ranges 0-4: If ADADL50= “No” or ADADL50= “Don’t know” then ADL23=0; else if ADADL50= “Yes” then ADL23= ADADL51;

If five or more items scores are missing, the total score will be missing. If less than five item scores are missing, the missing questions within the item score will be imputed by the worst case for each missing question (missing main responses will be imputed by 0; if the main response equal to “Yes”, missing subsequent question(s) will be imputed by the worst score for each question).

The ADCS-ADL_{23} total score ranges from 0 to 78, with a higher score indicating a higher functioning status.

Basic ADCS-ADL_{23} is defined as the sum of the item scores 1 to 6 (Usual Eating Performance, Optimal Walking Performance, Usual Bowel/Bladder Function, Usual Bathing Performance, Optimal Grooming Performance, and Dressing), and Instrumental ADCS-ADL_{23} is defined as the sum of the item scores 7 to 23. Basic-and Instrumental ADCS-ADL_{23} will be calculated after the imputation rule for missing item scores have been applied for the calculation of the ADCS-ADL_{23} total score. The basic ADCS-ADL_{23} ranges from 0 to 22, and Instrumental ADCS-ADL_{23} ranges from 0 to 56.

18.2.3.1 Activities of Daily Living – Basic (ADL-B) Total Score

The Basic Total Score of the ADCS-ADL_{23} is the sum of items 1 – 6 from the ADCS-ADL_{23} (Usual Eating Performance, Optimal Walking Performance, Usual Bowel/Bladder Function, Usual Bathing Performance, Optimal Grooming Performance, and Dressing). The ADL-B total score ranges from 0 – 22.

This score will be calculated after the imputation rule for missing item scores have been applied for the calculation of the ADCS-ADL_{23} total score.

18.2.3.2 Activities of Daily Living – Instrumental (ADL-I) Total Score

The Instrumental Total Score of the ADCS-ADL_{23} is the sum of items 7 – 23 in from the ADCS-ADL_{23}. The ADL-I total score ranges from 0 – 56.

This score will be calculated after the imputation rule for missing item scores have been applied for the calculation of the ADCS-ADL_{23} total score.

18.2.4 Composite Score for ADAS-Cog and ADCS-ADL_{23}

The composite score for ADAs-Cog and ADCS-ADL_{23} will be constructed by averaging the standardized scores (z-scores) for each scale, i.e. equal weights will be used for the scales. The z-scores for each scale will be computed by subtracting the mean total score at baseline from the individual subject total score and dividing by the standard deviation (SD) for the total score at baseline. In the calculation of the composite score, the sign for the z-score of ADAS-Cog will be reversed (-1*z-score), i.e. a positive composite score indicates an improvement.

18.2.5 Neuropsychiatric Inventory (NPI) Total Score

The NPI scale contains of 12 domains (Delutions, Hallucinations, Agitation/Aggression, Depression/Dysphoria, Anxiety, Elation/Euphoria, Apathy/Indifference, Disinhibition, Irritability/Lability, Aberrant Motor Behaviour, Sleep, and Appetite and Eating Disorders). The NPI total score is defined as the sum of the 12 domain scores, where the domain score

for each domain is calculated as (the domain is given by category 1-12 in the aCRF variable NPI01):

- If status (aCRF NPI02) is equal to "Not Applicable" or "No", the NPI domain score will be equal to 0; otherwise, the NPI domain score will be the product of frequency (aCRF NPI03, ranging from 1 to 4), and severity (aCRF NPI04, ranging from 1 to 3).
- If four or more domain scores are missing (due to missing record in status, or missing frequency, or severity for the domain), the NPI total score will be missing. If less than four domain scores are missing, the missing doimains will in the calculation of the NPI total score be imputed by the mean of the non-missing domain score rounded to the closest integer (.5 rounded upwards).

Each domain score ranges from 0 to 12, and the NPI total score ranges from 0 to 144 with a higher score indicates a more serious behavioural issue.

18.2.6 NPI Caregiver Distress Total Score

The NPI caregiver distress total score is calculated as the sum of the caregiver distress for each domain (aCRF NPI05, ranging from 0 to 5) and ranging from 0 to 60.

If caregiver distress for four or more domains is missing, the NPI caregiver distress total score will be missing. If less than four scores are missing, the missing domains of the NPI caregiver distress total score will be imputed by the mean of the non-missing scores, rounded to the closest integer (.5 rounded upwards).

18.2.7 EQ-5D Utility Score

The EQ-5D utility score will be derived from the EQ-5D questionnaire items mobility (aCRF EQ5DP01), self care (aCRF EQ5DP02), activity (aCRF EQ5DP03), pain (aCRF EQ5DP04), and anxiety (aCRF EQ5DP01). All items are scored from 1 (no problems) to 3 (extreme problems). The utility score will be calculated using the following SAS code where euro1-euro5 are the 5 individual item scores. If one or more item score is missing, the utility score will be missing. The utility score will be calculated according to Dolan P. et al. using the SAS code below.[8]

```
DATA eq5d;
    SET eq5d;
        IF (euro1 NOT IN (1,2,3) OR euro2 NOT IN (1,2,3) OR
        euro3 NOT IN (1,2,3) OR euro4 NOT IN (1,2,3) OR
        euro5 NOT IN (1,2,3)) THEN EQ5D_utility=.;
        ELSE DO;
            IF (SUM(OF euro1-euro5))=5 THEN c0=0;
            ELSE c0=0.081;
            IF (euro1=1) then c1=0;
            ELSE IF (euro1=2) THEN c1=0.069;
            ELSE IF (euro1=3) THEN c1=0.314;
```

```
            IF (euro2=1) THEN c2=0;
            ELSE IF (euro2=2) THEN c2=0.104;
            ELSE IF (euro2=3) THEN c2=0.214;
            IF (euro3=1) THEN c3=0;
            ELSE IF (euro3=2) THEN c3=0.036;
            ELSE IF (euro3=3) THEN c3=0.094;
            IF (euro4=1) THEN c4=0;
            ELSE IF (euro4=2) THEN c4=0.123;
            ELSE IF (euro4=3) THEN c4=0.386;
            IF (euro5=1) THEN c5=0;
            ELSE IF (euro5=2) THEN c5=0.071;
            ELSE IF (euro5=3) THEN c5=0.236;
            IF (MAX(OF euro1-euro5)=3) THEN c6=0.269;
            ELSE c6=0;
            EQ5D_utility=1-SUM(OF c0-c6);
        END;
RUN;
```

18.2.8 Dependence Level Score

The dependence level score, ranging from 0 (no dependence) to 5 (complete dependence), is based on the 13 items of the *Dependence Scale* described in Panel 10.

Panel 10 Items Dependence Scale

Item	eCRF variable and codes
Does the patient need reminders or advice to manage chores, do shopping, cooking, play games, or handle money?	DS01 0=No 1=Occasionally 2=Frequently
Does the patient need help to remember important things such as appointments, recent events, or names of family or friends?	DS02 0=No 1=Occasionally 2=Frequently
Does the patient need frequent (at least once a month) help finding misplaced objects, keeping appointments, or maintaining health or safety (locking doors, taking medication)?	DS03 0=No 1=Yes
Does the patient need household chores done for them?	DS04 0=No 1=Yes
Does the patient need to be watched or kept company when awake?	DS05 0=No 1=Yes
Does the patient need to be escorted when outside?	DS06 0=No 1=Yes
Does the patient need to be accompanied when bathing or eating?	DS07 0=No 1=Yes
Does the patient have to be dressed, washed, and groomed?	DS08 0=No 1=Yes
Does the patient have to be taken to the toilet to avoid incontinence?	DS09 0=No 1=Yes
Does the patient have to be fed?	DS10 0=No 1=Yes
Does the patient need to be turned, moved, or transferred?	DS11 0=No 1=Yes
Does the patient wear a diaper or catheter?	DS12 0=No 1=Yes
Does the patient need to be tube fed?	DS13

	0=No 1=Yes

If one or more item scores are missing, the dependence level score will be missing. The dependence level score will be calculated using the SAS code below:

```
DATA eff_DS_nom;
    SET eff_DS_nom;
    IF
    nrmiss(DS01,DS02,DS03,DS04,DS05,DS06,DS07,DS08,DS09,DS10,DS11,DS12,DS13)
    )>0
    THEN ds_TOT=.;
    ELSE IF DS11=1 or DS12=1 or DS13=1 then ds_TOT=5;
    ELSE IF DS08=1 or DS09=1 or DS10=1 then DS_TOT=4;
    ELSE IF DS05=1 or DS06=1 or DS07=1 then DS_TOT=3;
    ELSE IF ((DS01=1)+( DS02=1)+(DS03=1)) >=2 or DS01=2 or DS02=2 or DS04=1 then
    DS_TOT=2;
    ELSE IF DS01=1 or DS02=1 or DS03=1 then DS_TOT=1;
    ELSE DS_TOT=0;
RUN;
```

The dependence total score is defined as the sum of the 13 items, ranging from 0 to 15. If one or more item scores are missing, the dependence total score will be missing.

18.3 Assigning Data to Visits

This section describes rules for data to be used in descriptive analyses by visit week, and statistical analyses.

18.3.1 Rating Scales

The assessment at the Withdrawal Visit for patients withdrawn from treatment will be assigned to a nominal visit in the Treatment Period, according to the visit windowing specified in Panel 11 (ADAS-Cog, ADCS-CGIC, ADCS-AGL$_{23}$ and NPI), or Panel 12 (RUD Lite, EQ-5D, and Dependency Scale). The assessment collected at the schedule visit will be used in the analyses, or the windowed assessment from the Withdrawal Visit if no scheduled assessment is available. If the assessment at the Withdrawal Visit is assigned to the same visit as an assessment at a scheduled visit, the assessment from the scheduled visit will be used.

Panel 11 Visit Windows for assessments collected at Visit 3, Visit 5, and Visit 7

Nominal Visit Number	Nominal Visit Week	Nominal Visit Day	Time Window
V3	4	28	1 to 55
V5	12	84	56 to 125
V7 (Completion/Withdrawal)	24	168	>125

Panel 12 Visit Windows for assessments collected only at Visit 5, and Visit 7

Nominal Visit Number	Nominal Visit Week	Nominal Visit Day	Time Window
V5	12	84	1 to 125
V7 (Completion/Withdrawal)	24	168	>125

The efficacy assessments collected at the Withdrawal Follow-up Visit and Drop-out Retrieval Visits will only be included in a sensitivity analysis. Assessments at the Withdrawal Follow-up visit will be assigned to a nominal visit in the treatment period according to the visit windowing specified in Panel 12. Assessments at the Drop-out Retrieval Visit will be by definition assigned to Visit Week 24. If more than one assessment is assigned to the same visit, the priority rule for the assessment to be used in the sensitivity analysis will be the following: Drop-out Retrieval Visit, Withdrawal Follow-up Visit, Withdrawal Visit, and Scheduled visit.

18.3.2 Safety Variables

The first usable assessment at the Withdrawal Visit for safety variables (laboratory tests, vital signs, weight and ECGs) will be assigned to a nominal visit in the *treatment period*, according to the visit windowing specified in Panel 13.

Panel 13 Visit Windows for Clinical Safety Data

Nominal Visit Number	Nominal Visit Week	Nominal Visit Day	Time Window
V3	4	28	1 to 41
V4	8	56	42 to 69
V5	12	84	70 to 104
V6	18	126	105 to 146
V7 (Completion/Withdrawal)	24	168	>146

For assessments at the Screening Visit or at the Baseline Visit, the last usable assessment will be used. For assessments at visits post-baseline, the first usable assessment from the scheduled visit will be used in the analyses by visit, or the windowed assessment from the Withdrawal Visit will be used if no scheduled assessment is available.

18.4 Handling of Missing or Incomplete Dates/Times

18.4.1 IMP Start and Stop Dates

For patients in the APTS, missing IMP start date will be imputed with the randomisation date.

For patients with a missing IMP stop date, if it can be ascertained from other data that the patient did take IMP until a specific date, this date may be used to calculate exposure.

18.4.2 Donepezil Start Date

Donepezil treatment before baseline (screening visit) was recorded, where each change in dose, frequency, or route of administration in donepezil treatment prior to baseline was recorded as a new event.

Duration in years of donepezil treatment before baseline is calculated as (the number of days between start date of the first recorded donepezil treatment and the screening visit) divided by 365.25. In the calculation of duration, missing start month will be imputed by June and missing start day will be imputed by 15. The minimum of imputed start dates, complete start dates, and the date of screening visit will be used as start date.

18.4.3 Date of Alzheimer Diagnosis

Duration of Alzheimer diagnosis as baseline will be calculated as (the number of days between the date of diagnosis and the screening visit) divided by 365.25. In the calculation of duration, missing month of diagnosis will be imputed by June, and missing day of diagnosis will be imputed by 15. The minimum of the imputed date of diagnosis and the date of the screening visit will be used as the date of diagnosis.

18.4.4 Withdrawal Date

For withdrawn patients with a missing Withdrawal Visit, the date of the last attended visit in the *treatment period* will be used in the calculation of time to withdrawal from treatment and the calculation of compliance.

18.4.5 Medication Start and Stop Dates

Handling of missing medication start or stop dates are described in Panel 14.

Panel 14 Handling of Missing Dates in Classification of Medications

Medication Start Date	Medication Stop Date	Medication Classification
Unknown	< date of first dose of IMP	Discontinued prior to first dose of IMP
Unknown	≥ date of first dose of IMP	Started at or after first dose of IMP
< date of first dose of IMP	Unknown	Continued after first dose of IMP
≥ date of first dose of IMP	Unknown	Started at or after first dose of IMP
Unknown	Unknown	Started at or after first dose of IMP

18.4.6 Adverse Event Start and Stop Dates

If a stop date is missing due to an event being on-going, the last visit date will be used as the stop date in the classification of adverse events.

An adverse event with a missing or incomplete start or stop date will be classified as a pre-treatment adverse event if:

- The start date is missing or incomplete, and the stop date is prior to the first dose of IMP, or the stop date is incomplete but known to be prior to the first dose of IMP (stop day is missing and stop year and month is before the year and month of the first dose of IMP, or stop day and month are missing and stop year is before the year of first dose of IMP).
- The start date is incomplete but known to be prior to the first dose of IMP (start day is missing and start year and month is before the year and month of the first dose of IMP, or start day and month are missing and start year is before the year of first dose of IMP), and no change in intensity.

In all other cases of an adverse event with a missing or incomplete start or stop date, the event will be classified as a TEAE

18.5 Compliance

In the calculation of compliance with IMP in visit intervals, the Withdrawal Visit will be assigned to the closest scheduled visit not attended for withdrawn patients.

Compliance with IMP is reported since the previous visit. Therefore, if one or more visits have been missed between two scheduled visits, the compliance with IMP for visit interval(s) in the period including the missed visit(s) will be estimated by the compliance with IMP in the period.

If compliance reporting is missing at the last attended visit in the treatment period, then all days since the previous visit will be assumed to be non-compliant, and the number of days since previous visits will be added to the total number of days of non-compliance in the calculation of compliance.

18.6 Grouping of Small Sites

In analyses where country is a factor, countries where not all treatment groups are represented in the FAS will be grouped. The following stepwise procedure will be used to determine the grouping:

- Step 1 – All countries where not all treatment groups are represented in the FAS will be grouped into a single collective country within the same continent.
- Step 2 – If not all treatment groups are represented in the FAS for a grouped country, the countries will be grouped with the smallest country within the same continent for which all treatment groups are represented in the FAS. If there is more than one such country, the first country in ascending alphabetic order will be selected for the grouping.

In analyses where site is a factor, sites where not all treatment groups are represented in the FAS will be grouped. The following stepwise procedure will be used to determine the grouping:

- Step 1 – All sites where not all treatment groups are represented in the FAS will be grouped into a single collective site within the same country.
- Step 2 – If not all treatment groups are represented in the FAS for a grouped site, the sites will be grouped with the smallest site within the same country for which all treatment groups are represented in the FAS. If there is more than one such site, the first site in ascending alphabetic order will be selected for the grouping.

References

1. Siddiqui O, Hung HMJ, O'Neill R. MMRM vs. LOCF: A comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009; 19: 227-246.
2. Ayele et al., A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials, Journal of Biopharmaceutical Statistics, 24: 211-228, 2014.
3. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics. 1996; 52: 1324-1333.
4. Rubin, DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1997.
5. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures.
6 Alireza Atri, Suzanne B Hendrix, Pejović V, Hofbauer R, Edwards J, Molinuevo J, and Graham S. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies inmoderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Alzheimers Res Therapy December 2015, 7:28.
7 United States Food and Drug Administration (FDA). Guidance for Industry: Drug-induced liver injury Preparketing Clinical Evaluation. July 2009.
8. Dolan P, Gudex C, Kind P. A social tariff for EuroQol: Results from a UK general population survey. Discussion paper No. 138. Centre for health economics, University of New York, 1995.

Appendix I

Statistical Analysis Plan

Authentication and Authorisation

Statistical Analysis Plan
Authentication and Authorisation

Study title:	Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of idalopirdine in patients with mild-moderate Alzheimer's disease treated with donepezil; Study 2
SAP date:	29 April 2016

This document has been signed electronically. The signatories are listed below.

Authentication

Biostatistician:	Lars Lau Raket
CRS:	Maiken Brix Schou, CRD Neurology Idalopirdine Team

Authorisation

Head of Biostatistics:	Anna Karina Trap Huusom

Appendix II

Study Flow Chart

Study Flow Chart

Table 1 Study Flow Chart

Visit	Screen-ing	Base-line[a]	Treatment Period				Completion/ Withdrawal[b]	Safety/ Withdrawal Follow-up[c]	Drop-out Retrieval[n]
Visit Number	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**
Day[d]/ End of Week	**-14 to -1**	**0**	**28/ 4**	**56/ 8**	**84/ 12**	**126/ 18**	**168/ 24**	**196/ 28**	**168 24[o]**
Visit Window[e] (days relative to nominal visit)			**± 7d**	**± 7d**	**± 7d**	**± 7d**	**± 7d**	**+ 7d**	**± 7d**
Screening/Baseline Procedures and Assessments									
Signed informed consent	√								
Diagnosis NINCDS-ADRDA	√								
MMSE	√	√					√		
Disease-specific history	√								
NINDS-AIREN	√								
Relevant history (social, medical, psychiatric, neurological)	√								
Years of education	√								
Magnetic resonance imaging / Computerised tomography[f]	√								
Demographics (age, sex, race)	√								
Nicotine and alcohol use	√								
Height	√								
Blood sampling for genotyping ApoE, CYP[g]		√							
Inclusion/exclusion criteria	√	√							
Randomisation		√							
Efficacy Assessments									
ADAS-Cog	√	√	√		√		√	√[h]	√
$ADCS\text{-}ADL_{23}$		√	√		√		√	√[h]	√
ADCS-CGIC		√	√		√		√	√[h]	√
NPI		√	√		√		√		

Visit	Screen-ing	Base-line[a]	Treatment Period				Completion/ Withdrawal[b]	Safety/ Withdrawal Follow-up[c]	Drop-out Retrieval[n]
Visit Number	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**
Day[d]/ End of Week	**-14 to -1**	**0**	**28/ 4**	**56/ 8**	**84/ 12**	**126/ 18**	**168/ 24**	**196/ 28**	**168 24[o]**
Visit Window[e] (days relative to nominal visit)			**± 7d**	**± 7d**	**± 7d**	**± 7d**	**± 7d**	**+ 7d**	**± 7d**
Pharmaco-economic Assessments									
RUD-Lite		√			√		√		
EQ-5D-3L		√			√		√		
Dependence scale		√			√		√		
Pharmacokinetic Assessments[i]									
Blood sampling for Lu AE58054 and donepezil hydrochloride		√	√	√	√	√	√		
Exploratory Biomarker Assessments									
Blood sampling for gene expression profiling[i]		√							
Blood sampling for metabolomics /proteomics[i]		√							
Blood sampling for pharmacogenetics (optional)[j]		√							
Safety Assessments									
Adverse events[k]	√	√	√	√	√	√	√	√[l]	√[p]
Blood and urine sampling for clinical safety laboratory tests	√	√	√	√	√	√	√		
Vital signs, weight, ECGs	√	√	√	√	√	√	√		
Examinations (physical, psychiatric, neurological)	√	√		√		√	√		
C-SSRS	√	√	√	√	√	√	√		
Other Study Procedures									
IMP and donepezil hydrochloride dispensed		√	√	√	√	√			
IMP and donepezil hydrochloride returned, accountability tracked			√	√	√	√	√		
Recent and concomitant medication	√	√	√	√	√	√	√	√	√[q]

Visit	Screen-ing	Base-line[a]	Treatment Period				Completion/ Withdrawal[b]	Safety/ Withdrawal Follow-up[c]	Drop-out Retrieval[n]
Visit Number	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**
Day[d]/ End of Week	**-14 to -1**	**0**	**28/ 4**	**56/ 8**	**84/ 12**	**126/ 18**	**168/ 24**	**196/ 28**	**168 24[o]**
Visit Window[e] (days relative to nominal visit)			**± 7d**	**± 7d**	**± 7d**	**± 7d**	**± 7d**	**+ 7d**	**± 7d**
Patient identification card dispensed		√							
Patient identification card returned							√[m]		

a In exceptional cases, the visit interval between the Screening and Baseline Visit may be extended with consent from the Medical Expert, provided the Medical Expert accepts the rational for the extension.

b This visit should take place as soon as possible after the patient withdraws from the study. Patients completing the 24 week Treatment Period may be eligible to enter a 6-month open-label extension study with Lu AE58054 and donepezil.

c Patients who complete the study without entering the open-label extension study will have a Safety Follow-up Visit (no efficacy assessments) which is at least 4 weeks (+ up to 7 days) after last dose of IMP. Patients withdrawn will likewise be followed-up 4 weeks (+ up to 7 days) after withdrawal except for those who withdraw their consent. This follow-up will include safety and selected efficacy assessments. Patients who withdraw their consent should still have a safety follow-up (without efficacy assessment) but the visit must only be recorded in the medical records.

d All assessments can be completed over a maximum of two consecutive days, in this case the first day should be considered as the visit day of the study. Note: If a visit takes place over two consecutive days IMP should be dispensed on the second day, after all assessments have been performed. For visits other than the Baseline visit, the visit window must allow for the previously dispensed IMP to last for both visit days.

e If the date of a patient visit does not conform to the study plan, subsequent visits should be planned to maintain the visit schedule relative to Randomisation/Baseline. The number of days between two visits (except for the Drop-out Retrieval Visit) must not exceed the number of days for which IMP is provided in the wallet cards.

f A scan performed within the previous 12 months may be used to assess eligibility. If no such scan is available, the Magnetic Resonance Imaging (MRI)/Computerised tomography (CT) should be performed at the Screening Visit or between the Screening and the Baseline visit. No central reading will be done.

g Blood sampling for determining genetic variation for apolipoprotein E (ApoE3, ApoE4) and cytochrome P450 drug metabolising enzymes (CYP2C19, CYP2D6) will be done at the Baseline Visit.

h Efficacy assessments only for patients withdrawn.

i Sampling for drug bioanalysis, exploratory gene expression profiling (mRNA) and metabolomics/proteomics is an integrated part of the study and is covered by the main Patient Information Sheet. These blood samples should preferably be collected with the safety laboratory samples, as appropriate.

j Sampling for pharmacogenetics is optional and a separate *Patient Information Sheet* covers this analysis. This sampling should preferably be at the Baseline Visit but may be collected at any visit that includes a clinical safety laboratory sample.

k Signs and symptoms present at screening and/or baseline (before IMP intake) must be recorded on an *Adverse Event Form*.

l Only for adverse events ongoing at Completion/Withdrawal and new SAEs

m Patient Identification Card should only be returned after the last dose of IMP has been taken, that is at the end of the treatment period.

n Withdrawn patients, except for those who withdraw their consent or discontinue their participation to the study at or after week 18 (Visit 6), will be scheduled for a Drop-out Retrieval Visit.

o Projected Week 24 visit, the visit that the patient should have been attending, provided he/she had not been withdrawn from the study.

p Only for adverse events ongoing at previous visit and new SAEs which are considered as possibly/probably related to IMP by investigator.

q Only for concomitant medications ongoing at the day of the Drop-out Retrieval Visit.

Appendix III

SAS® Code

SAS® Code

The SAS code for the primary MMRM-analysis will be:

```
%**MMSTR=MMSE stratum;

proc mixed noclprint data=ADAS ic method=REML;
    class usubjid country analysis_week armcd MMSSTR;
    model ADASTOT_DL = ADASTOT_BL MMSSTR country armcd analysis_week
        armcd*analysis_week  MMSSTR*analysis_week ADASTOT_BL*analysis_week
        /s DDFM=KR;
    repeated analysis_week/subject=usubjid type=un;
    lsmeans armcd*analysis_week/ diff cl alpha=0.05;
run;
```

The SAS code for the sensitivity analysis using a pattern mixture model will be:

```
%**Prepare data on the form needed for proc MI: one column for each visit Week 4, 12, and
24;

proc transpose data=ADAS out=ADAS_w prefix=ADASTOT_DL_w;
    var ADASTOT_DL;
    by usubjid country armcd MMSSTR ADASTOT_BL COMPLFL lastweek;
    id analysis_week;
run;

%**Impute non-monotone missing observation to make sure that datasets only has monotone
missing values left;

proc sort data = ADAS_w;
```

```
      by armcd MMSSTR;
run;


proc mi data = ADAS_w out = AllMono nimpute = 200 seed = 17345;
      by armcd MMSSTR;
      var  ADASTOT_BL ADASTOT_DL_w4 ADASTOT_DL_w12 ADASTOT_DL_w24;
      mcmc chain = multiple impute = monotone;
      ods output MissPattern=mp;
run;


%**Impute monotone missing values, using pattern in the placebo group (armcd='A');
%*** Do one imputation per imputed dataset from previous step, i.e nimpute=1 in this step;
proc mi data=AllMono seed=4387410 nimpute=1 out=out_mi;
   class armcd country MMSSTR;
   monotone reg ();
   mnar model( ADASTOT_DL_w4 ADASTOT_DL_w12 ADASTOT_DL_w24 /modelobs=
(armcd='A')); * use mnar specification to impute from a model determined by the modelobs=
parameter;
   var  country MMSSTR ADASTOT_BL ADASTOT_DL_w4 ADASTOT_DL_w12
ADASTOT_DL_w24;
run;


%**Prepare data for MMRM analysis ;
%**If not withdrawn from treatment (COMPLFL=1), imputed monotone values will be re-set
to missing;
%**Note, lastweek is >=4, since analysis will be based on the same patients as in the primary
analysis
```

```
where patients without valid post-baseline obs are excluded;
data out_mi_Anl(drop=ADASTOT_DL_w4 ADASTOT_DL_w12 ADASTOT_DL_w24);
      set out_mi;
      analysis_week=4 ;
      ADASTOT_DL=ADASTOT_DL_w4;
      output;
      analysis_week=12 ;
      if complfl=1 and lastweek=4 then ADASTOT_DL=.;
      else ADASTOT_DL=ADASTOT_DL_w12;
      output;
      analysis_week=24 ;
      if complfl=1 and lastweek IN (4 12) then ADASTOT_DL=.;
      else ADASTOT_DL=ADASTOT_DL_w24;
      output;
run;
proc sort data=out_mi_Anl;
      by _Imputation_
      analysis_week;
run;

%**MMRM-analysis by imputed datasets using the same model as in the primary analysis;
proc mixed noclprint data = out_mi_Anl ic method=REML;
      by _imputation_;
      class usubjid country analysis_week Armcd MMSSTR;
      model ADASTOT_DL = ADASTOT_BL MMSSTR country armcd analysis_week
```

```
        armcd*analysis_week  MMSSTR*analysis_week ADASTOT_BL*analysis_week/s
DDFM=KR;

    repeated analysis_Week/subject=usubjid type=un;

    lsmeans Armcd*analysis_Week/ diff cl alpha=0.05;

    ods output diffs=MIdiffs;

    ods output LSMeans=MILSM;

run;


%**Combines the results  of the analyses of the 200 complete datasets generated by
simulations;

%**Note that the treatment effect is reversed (PBO-active);

proc sort data=MIdiffs(where=(analysis_week=24 and analysis_week=_analysis_week  and
armcd='A')) out=MIdiffs2;

    by _armcd;

run;

proc mianalyze parms= MIdiffs2;

    by _armcd;

    modeleffects armcd*analysis_week ;

    ods output ParameterEstimates = MIdiffs_ana;
run;
```

Appendix IV

PCS Criteria

PCS Criteria

Table 2 PCS Criteria for Clinical Safety Laboratory Tests

Category and Abbreviation	Test (units)	Type	PCS Criterion Low	PCS Criterion High
Liver				
AST	Aspartate aminotransferase (IU/L)	1		≥ 3 × ULN
ALT	Alanine aminotransferase (IU/L)	1		≥ 3 × ULN
BILI	Bilirubin (µmol/L)	1		≥ 34
BILDIR	Direct bilirubin (µmol/L)	1		≥ 12
ALP	Alkaline phosphatase (IU/L)	1		≥ 3 × ULN
GGT	Gamma glutamyl transferase (IU/L)	1		≥ 200
Kidney				
CREAT	Creatinine (µmol/L)	1	≤ 0.5 × LLN	≥ 1.5 × ULN
BUN	Blood urea nitrogen (mmol/L)	1	≤ 0.75	≥ 11
Electrolytes				
SODIUM	Sodium (mmol/L)	1	≤ 125	≥ 155
K	Potassium (mmol/L)	1	≤ 3.0	≥ 6.0
CA	Calcium (mmol/L)	1	≤ 1.8	≥ 3.0
BICARB	Bicarbonate (mmol/L)	1	≤ 12	≥ 38
Endocrine/Metabolic				
GLUC	Serum glucose (mmol/L)	1	≤ 3.9	≥ 9.0
GLUC	Serum glucose, fasting (mmol/L)	1	≤ 3.5	≥ 8.1
TSH	Thyrotropin (mIU/L)	1	≤ 0.3	≥ 5.5
ALB	Albumin (g/L)	1	≤ 27	
Lipids				
CHOL	Cholesterol (mmol/L)	1		≥ 7.8
CHOL	Cholesterol, fasting (mmol/L)	1		≥ 6.2
TRIG	Triglycerides (mmol/L)	1		≥ 5.65
TRIGLY	Triglycerides, fasting (mmol/L)	1		≥ 4.2
Haematology/Coagulation				
INR	Prothrombin ratio	1		≥ 2.0
PLAT	B-thrombocytes platelet count (x10E9/L)	1	≤ 75	≥ 600
HGB	Haemoglobin (g/dL)	1	≤ 9.5 (female) ≤ 11.5 (males)	≥ 16.5 (females) ≥ 18.5 (males)
RBC	Erythrocytes (×10E12/L)	1	≤ 3.5 (female) ≤ 3.8 (males)	≥ 6.0 (females) ≥ 7.0 (males)
WBC	Leukocytes (×10E9/L)	1	≤ 2.8	≥ 16
NEUTLE	Neutrophils of leukocytes (%)	1	≤ 20	≥ 85

Category and Abbreviation	Test (units)	Type	PCS Criterion Low	PCS Criterion High
EOSLE	Eosinophils of leukocytes (%)	1		≥ 10
BASOLE	Basophils of leukocytes (%)	1		≥ 10
LYMPHLE	Lymphocytes of leukocytes (%)	1	≤ 10	≥ 75
MONOLE	Monocytes of leukocytes (%)	1		≥ 15
Infection				
S-CRP	C-reactive protein (mg/L)	1		≥ 25
Urine				
GLUC	U-Glocose			Increase≥ 2
KETONES	U-Ketones			Increase≥ 2
OCCBLD	U-Occult Blood			Increase≥ 2

1 = continuous

Table 3 PCS Criteria for Vital Signs and Weight

CDISC term	Variable (units)	Type	PCS Criterion Low	PCS Criterion High
WEIGHT	Weight (kg)	1, 2	Decrease ≥ 7%	Increase ≥ 7%
BMI	Body mass index (kg/m2)	1, 2	Decrease ≥ 7%	Increase ≥ 7%
DIABP	Supine diastolic blood pressure (mmHg)	1	≤ 50 and decrease ≥ 15	≥ 105 and increase ≥ 15
SYSBP	Supine systolic blood pressure (mmHg)	1	≤ 90 and decrease ≥ 20	≥ 180 and increase ≥ 20
PULSE	Supine pulse rate (bpm)	1	≤ 50 and decrease ≥ 15	≥ 120 and increase ≥ 15

1 = continuous, 2 = categorical

Table 4 PCS Criteria for ECG Parameters

CDISC term	Parameter (units)	Type	PCS Criterion Low	PCS Criterion High
PRMEAN	PR interval (msec)	1	< 120	≥ 250
QRSDUR	QRS interval (msec)	1	< 40	≥ 150
QTMEAN	QT interval (msec)	1	< 280	≥ 500
QTcB	QTcB interval (msec)	1	< 340	> 500 or change > 60 (a)
QTcF	QTcF interval (msec)	1	< 340	> 500 or change > 60 (a)
HRMEAN	Ventricular rate (bpm)	1	≤ 50 and decrease ≥ 15	≥ 120 and change ≥ 15 (a)

1 = continuous, (a) change relative to baseline

Electronic Signature Page

Full Title
Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil; study 2

Short Title
14862A - Statistical Analysis Plan Amendment - 2

Study Number 14862A

The following persons have electronically signed this document

Server Date and Time	Signed by
28-Nov-2016 22:27:09	AKTH Anna Karina Trap Huusom
Reason for Signature	Management Approval

29-Nov-2016 08:14:12	MBRS Maiken Brix Schou
Reason for Signature	Clinical Approval

29-Nov-2016 11:59:49	LLRA Lars Lau Raket
Reason for Signature	Biostatistic Approval

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Reason for Signature	

Statistical Analysis Plan – Amendment 2

Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil; study 2

Idalopirdine

Study No.:	14862A
Sponsor:	H. Lundbeck A/S (Lundbeck)
	2500 Valby (Copenhagen), Denmark
Biostatistician:	Lars Lau Raket, Biostatistics
SAP date:	29 April 2016
SAP Amendment date:	24 November 2016

1 Rationale for this SAP Amendment

This amendment specifies additional efficacy analyses of key interest. The analyses are similar to the mixed-model repeated-measurements (MMRM) analyses for the primary and key secondary endpoints specified in the statistical analysis plan, but include additional baseline or screening covariates. The rationale for including the additional covariates is that they have been found to be predictive of change from baseline at week 24 based on data from other studies, and thus these analyses increase the power of detecting treatment effects.

2 Additional Efficacy Analyses of Key Interest

The additional efficacy analyses of key interest follow the MMRM methodology for the primary and key secondary endpoints described in Chapter 10 of the Statistical Analysis Plan.

For the MMRM analysis of the primary endpoint specified in Section 10.2.1 of the statistical analysis plan, an analysis is added using the same model that in addition includes an MMSE total score at screening-by-week interaction, an MMSE total score at baseline-by-week interaction, and an ADAS-cog total score at screening-by-week interaction.

For the MMRM analyses of the key secondary endpoints specified in Section 10.3.1 of the statistical analysis plan, an additional analysis for each endpoint is added. The analyses use the same model as specified in Section 10.3.1, but furthermore include an MMSE total score at screening-by-week interaction and an MMSE total score at baseline-by-week interaction.

Statistical Analysis Plan – Amendment 2
Authentication and Authorisation

Study title:	Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil; study 2
Study No.:	14862A
SAP Amendment date:	24 November 2016

This document has been signed electronically. The signatories are listed below.

Authentication

Biostatistician:	Lars Lau Raket
Clinical research scientist/Clinical pharmacology scientist:	Maiken Brix Schou, CRD Neurology

Authorisation

Head of Biostatistics:	Anna Karina Trap Huusom